Pyrrolidine derivatives and methods of use

Abstract

The present disclosure relates to compounds and pharmaceutical compositions thereof, and methods of using the compounds and compositions in therapy, such as methods of treating cancer.

Description

[Technical Field]

[0001] Related applications

[0001] This application claims priority and interest in U.S. Provisional Patent Application No. 63 / 119,621, filed on 30 November 2020, which is incorporated herein by reference in its entirety.

[0002] Technical field

[0002] This disclosure relates to compounds and methods of using such compounds in therapy. This disclosure further relates to the use of the compounds described herein or their pharmaceutically acceptable compositions for the prevention and / or treatment of hyperproliferative disorders such as cancer. The compounds described herein or their pharmaceutically acceptable compositions may also be found to be used in therapies for the treatment of diseases or indications related to VHL activity. [Background technology]

[0003]

[0003] There is a continuing need for small molecule compounds that can be found to be used in therapies, such as to treat hyperproliferative disorders like cancer. [Overview of the Initiative]

[0004]

[0004] In one embodiment, the present disclosure relates to a compound of formula (I): [ka] or its stereoisomer or tautomer, or any of the aforementioned pharmaceutically acceptable salts [in the formula, I)L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 teeth, i) One or more R s It may be replaced with -OC 6-20 It is aryl; here, R s Each instance is independently a halo; ii) One or more Rs a 4-20 membered heterocyclyl optionally substituted by; wherein R s is, independently at each occurrence, -C(O)O-C 1-6 alkyl; iii) a 5-20 membered heteroaryl, wherein R 2 the 5-20 membered heteroaryl is substituted by one or more R s ; wherein R s is, independently at each occurrence, halo, C 1-12 alkyl; iv) C optionally substituted by one or more R s 6-20 cycloalkyl; wherein R s is, independently at each occurrence, -C(O)O-C 1-6 alkyl, or II) L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; wherein the C 1 of L 1-12 alkyl may be optionally substituted by one or more R e ; wherein R e is, independently at each occurrence, C 1-6 alkyl or hydroxy C 1-6 alkyl; R 1 is i) -L 3 -C 6-20 aryl; wherein L 3 is O or C(O)NH; the C 3 -C 6-20 aryl C 6-20 aryl may be optionally substituted by one or more R s , wherein R s is, independently at each occurrence, halo C 1-6 alkyl; ii) C optionally substituted by one or more R s 4-20 cycloalkyl, wherein R s ​​Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl; iii) One or more R s Even if replaced by C 6-20 It is aryl; here, R s Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R s The 5-20 member heteroaryls have one or more ring atoms independently selected from N and O; R s The 5-20 member heteroaryls are one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 1-6 It is alkyl; iv) One or more R s It is a 5-20 member heteroaryl which may be substituted with; where R s Each instance independently produces a halo, amine, and C. 1-6 Alkyl, or C 6-20 It is an allele; R s C 6-20 A aryl is one or more R t It may also be replaced with; here, R t Each instance is independently a halo; v) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Aryl, or C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; R t Each occurrence is independent of C 6-20 It is Ariel, R s C 6-20 A aryl is one or more R uIt may also be replaced with; R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. This applies to the following.

[0005]

[0005] In another embodiment, the present disclosure relates to a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described herein, and one or more pharmaceutically acceptable additives.

[0006]

[0006] In one embodiment, the present disclosure relates to a method of using a compound of formula (I), or one or more of the compounds described herein, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt thereof, or one or more of the pharmaceutical compositions described herein, for the treatment of a disease or indication related to VHL activity.

[0007]

[0007] In further embodiments, the Disclosure relates to methods for preventing or treating hyperproliferative disorders, anemia, or ischemia by administering one or more of the compounds described herein, or their stereoisomers or tautomers, or any pharmaceutically acceptable salts thereof, or one or more of the pharmaceutical compositions described herein, to a subject in need thereof. In some embodiments, the hyperproliferative disorder is cancer, and the subject is human. In some embodiments, the hyperproliferative disorder is a solid tumor. In some such embodiments, the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma.

[0008]

[0008] In another embodiment, the compound of formula (II) is provided: [ka] or its stereoisomer or tautomer, or any of the aforementioned pharmaceutically acceptable salts [in the formula, I)L 1 -R 1 It is methyl; L2 is a bond or C 1-12 alkyl; R 2 is i) one or more R s -O-C optionally substituted by 6-20 aryl; wherein R s at each occurrence is independently halo; ii) one or more R s 4- to 20-membered heterocyclyl optionally substituted by; wherein R s at each occurrence is independently -C(O)O-C 1-6 alkyl; iii) 5- to 20-membered heteroaryl, wherein the 5- to 20-membered heteroaryl of R 2 is substituted by one or more R s ; wherein R s at each occurrence is independently halo or C 1-12 alkyl; iv) one or more R s C optionally substituted by 6-20 cycloalkyl; wherein R s at each occurrence is independently -C(O)O-C 1-6 alkyl; v) -N(CH3)-C 6-20 aryl; vi) one or more R s -C optionally substituted by 6-20 aryl, wherein R s at each occurrence is independently C 1-6 haloalkyl; or II) L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; wherein the C 1 of L 1-12 alkyl may be optionally substituted by one or more R e ; wherein R e at each occurrence is independently C 1-6 alkyl or hydroxy C1-6 It is alkyl; R 1 teeth, i)-L 3 -C 6-20 It is aryl; here, L 3 is O or C(O)NH; -L 3 -C 6-20 Ariel's C 6-20 A aryl is one or more R s It may also be replaced with, where R s Each appearance is independent of Haro C 1-6 It is alkyl; ii) One or more R s Even if replaced by C 4-20 It is a cycloalkyl, where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl; iii) One or more R s Even if replaced by C 6-20 It is aryl; here, R s Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R s The 5-20 member heteroaryls have one or more ring atoms independently selected from N and O; R s The 5-20 member heteroaryls are one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 1-6 It is alkyl; iv) One or more R s It is a 5-20 member heteroaryl which may be substituted with; where R s Each instance independently produces a halo, amine, and C. 1-6 Alkyl, or C 6-20 It is an allele; R s C 6-20 A aryl is one or more R t It may also be replaced with; here, R t Each occurrence is independently a halo; or v) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Aryl, or C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 6-20 It is Ariel, R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. It will be provided.

[0009]

[0009] It should be understood that any method of preparing or using the compound of formula (I) also applies to the compound of formula (II). The present invention provides, for example, the following items: (Item 1) Compound of formula (I): [ka] or its stereoisomer or tautomer, or any of the aforementioned pharmaceutically acceptable salts [in the formula, I) L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 teeth, i) One or more R s It may be replaced with -OC 6-20 It is aryl; here, R s Each instance is independently a halo; ii) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl; iii) A 5-20 member heteroaryl, where R 2 The 5-20 member heteroaryls are one or more R s It is replaced by; here, R s Each appearance is independent of whether it is a halo or C. 1-12 It is alkyl; iv) One or more R s Even if replaced by C 6-20 It is a cycloalkyl; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl, or, II) L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 teeth, i)-L 3 -C 6-20 It is aryl; here, L 3 is O or C(O)NH; -L 3 -C 6-20 Ariel's C 6-20 A aryl is one or more Rs It may also be replaced with, where R s Each appearance is independent of Haro C 1-6 It is alkyl; ii) One or more R s Even if replaced by C 4-20 It is a cycloalkyl, where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl; iii) One or more R s Even if replaced by C 6-20 It is aryl; here, R s Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R s The 5-20 member heteroaryls have one or more ring atoms independently selected from N and O; R s The 5-20 member heteroaryls are one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 1-6 It is alkyl; iv) One or more R s A 5-20 member heteroaryl which may be substituted with; where R s Each instance independently produces a halo, amine, and C. 1-6 Alkyl, or C 6-20 It is an allele; R s C 6-20 A aryl is one or more R t It may also be replaced with; here, R t Each occurrence is independently a halo; or v) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Aryl, or C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 6-20 It is Ariel, R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. (Item 2) L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 teeth, i) One or more R s It may be replaced with -OC 6-20 It is aryl; here, R s Each instance is independently a halo; ii) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl; iii) A 5-20 member heteroaryl, where R 2 The 5-20 member heteroaryls are one or more R s It is replaced by; here, R s Each appearance is independent of whether it is a halo or C. 1-12 It is alkyl; iv) One or more R s Even if replaced by C 6-20 It is a cycloalkyl; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl. The compounds listed in item 1, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts mentioned above. (Item 3) L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 teeth, i)-L 3 -C 6-20 It is aryl; here, L 3 is O or C(O)NH; -L 3 -C 6-20 Ariel's C 6-20 A aryl is one or more R s It may also be replaced with, where R s Each appearance is independent of Haro C 1-6 It is alkyl; ii) One or more R s Even if replaced by C 4-20 It is a cycloalkyl, where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl; iii) One or more R s Even if replaced by C 6-20 It is aryl; here, R s Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R s The 5-20 member heteroaryls have one or more ring atoms independently selected from N and O; R s The 5-20 member heteroaryls are one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 1-6 It is alkyl; iv) One or more R s A 5-20 member heteroaryl which may be substituted with; where R s Each instance independently produces a halo, amine, and C. 1-6 Alkyl, or C 6-20 It is an allele; R s C 6-20 A aryl is one or more R t It may also be replaced with; here, R t Each occurrence is independently a halo; or v) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Aryl, or C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 6-20 It is Ariel, R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. The compounds listed in item 1, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts mentioned above. (Item 4) L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 is one or more R s It may be replaced with -OC 6-20 It is aryl, and here, R s Each instance of appearance is independently a halo. The compounds described in item 1 or 2, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts described above. (Item 5) L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 is one or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl. The compounds described in item 1 or 2, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts described above. (Item 6) L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 R is a 5-20 member heteroaryl, where R 2 The 5-20 member heteroaryls are one or more R s It is replaced by; here, R s Each appearance is independent of whether it is a halo or C. 1-12 It is alkyl. The compounds described in item 1 or 2, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts described above. (Item 7) L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 is one or more R s Even if replaced by C 6-20 It is a cycloalkyl; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl. The compounds described in item 1 or 2, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts described above. (Item 8) L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 is -L 3 -C 6-20 It is aryl; here, L 3 is O or C(O)NH; -L 3 -C 6-20 Ariel's C 6-20 A aryl is one or more R s It may also be replaced with, where R s Each appearance is independent of Haro C 1-6 It is alkyl. The compounds described in item 1 or 3, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts described above. (Item 9) L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 is one or more R s Even if replaced by C 4-20 It is a cycloalkyl; where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl. The compounds described in item 1 or 3, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts described above. (Item 10) L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 is one or more R s Even if replaced by C 6-20 It is aryl; here, R s Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R s The 5-20 member heteroaryls have one or more ring atoms independently selected from N and O; R s The 5-20 member heteroaryls are one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 1-6 It is alkyl. The compounds described in item 1 or 3, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts described above. (Item 11) L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 is one or more R s A 5-20 member heteroaryl which may be substituted with; where R s Each instance independently produces a halo, amine, and C. 1-6 Alkyl, or C 6-20 It is an allele; R s C 6-20 A aryl is one or more R t It may also be replaced with; here, R t Each instance of appearance is independently a halo. The compounds described in item 1 or 3, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts described above. (Item 12) L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 is one or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Aryl, or C1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 6-20 It is Ariel, R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. The compounds described in item 1 or 3, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts described above. (Item 13) L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 teeth,

change

change

change

change

change

change

change

change

change

[0010]

[0010] This disclosure relates to compounds and pharmaceutically acceptable salts thereof.

[0011]

[0011] The subject matter disclosed herein is fully described below. However, many modifications and other embodiments of the subject matter disclosed herein, as described herein, will be conceivable to those skilled in the art who are interested in the teachings presented herein. Therefore, the subject matter disclosed herein should not be limited to the specific embodiments disclosed herein, and modifications and other embodiments should be considered to be intended to be included within the scope of the appended claims. In other words, the subject matter described herein covers substitutes, modifications, and equivalents. If one or more incorporated documents, patents, and similar materials differ from or conflict with this application, including, non-limitingly, the terms defined, the usage of terms, the technology described, etc., this application shall prevail. Unless otherwise defined, the technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs, when applied in the context in which they are used to describe this disclosure. The terms used herein are used solely to describe specific embodiments and are not intended to limit this disclosure. All publications, patent applications, patents, and other references mentioned herein are incorporated in their entirety by reference.

[0012] I. Definition

[0012] The term "group" refers to a component that is covalently bonded to another component.

[0013]

[0013] The terms "covalently bound" or "covalently linked" refer to a chemical bond formed by the sharing of one or more electron pairs.

[0014]

[0014] As used herein, unless otherwise defined in the claims, the term “optionally, may” means that the following event may or may not occur, and includes both the event that occurs and the event that does not occur.

[0015]

[0015] As used herein, unless otherwise defined in the claims, “may be substituted,” “substituted,” or variations thereof mean optional substitutions involving multiple degrees of substitution by one or more substituents, e.g., 1, 2, 3, 4, or 5. This phrase should not be construed as overlapping with substitutions described and illustrated herein.

[0016]

[0016] As used herein, the term "alkyl" refers to a group of 1 to 12 carbon atoms (C1 to C12 12A saturated linear or branched monovalent hydrocarbon radical having any length of ) is referred to, where the alkyl radical may be independently substituted with one or more substituents as described herein. In another embodiment, the alkyl radical is 1 to 8 carbon atoms (C1-C8), or 1 to 6 carbon atoms (C1-C6), or 1 to 4 carbon atoms (C1-C4), or 1 to 3 carbon atoms (C1-C3). Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, isopropyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s- Butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl(t-Bu, t-butyl, tert-butyl, -C(CH3)3), 1-pentyl(n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl(-CH(CH3)CH2CH2CH3), 3-pentyl(-CH(CH2CH3)2), 2-methyl-2-butyl(-C(CH3)2CH2CH3), 3-methyl-2-butyl(-CH(CH3)CH(CH3)2), 3-methyl-1-butyl(-CH2CH2CH(CH3)2), 2-methyl-1-butyl(-CH2CH(CH3)CH2CH3), 1-hexyl(-CH2CH2CH2CH2CH2CH3), 2-hexyl(-CH(CH3)CH2CH2CH2CH3), 3-hexyl(-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl(-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl(-CH(CH3 This includes )CH(CH3)CH2CH3), 4-methyl-2-pentyl(-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl(-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl(-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl(-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl(-CH(CH3)C(CH3)3), 1-heptyl, 1-octyl, etc.

[0017]

[0017] As used herein, the term "alkylene" refers to a group of 1 to 12 carbon atoms (C1 to C12 12 A saturated linear or branched divalent hydrocarbon radical having any length of ) is used, where the alkylene radical may be independently substituted with one or more substituents as described herein. In another embodiment, the alkylene radical is 1 to 8 carbon atoms (C1-C8), 1 to 6 carbon atoms (C1-C6), or 1 to 4 carbon atoms (C1-C4). Examples of alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), and the like.

[0018]

[0018] The terms "carbocyclic," "carbocyryl," "cyclic carbon," and "cycloalkyl" refer to a monocyclic ring consisting of 3 to 12 carbon atoms (C3-C3). 12This refers to a monovalent, non-aromatic saturated or partially unsaturated ring having 7 to 12 carbon atoms as a polycyclic (e.g., bicyclic) ring. A bicyclic carbocyclic ring having 7 to 12 atoms may be configured as, for example, a bicyclo[4,5], [5,5], [5,6], or [6,6] system, and a bicyclic carbocyclic ring having 9 or 10 ring atoms may be configured as a bicyclo[5,6] or [6,6] system or a bridging system, for example, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. A polycyclic (e.g., bicyclic) ring that is fully saturated or partially unsaturated as a whole is encompassed within the definitions of the terms “carbocyclic,” “carbocyryl,” “cyclic carbon,” and “cycloalkyl,” and also includes cases where one or more of the fusion rings of a polycyclic ring are fully unsaturated (i.e., aromatic). Spiro moieties are also included within the scope of this definition. Examples of monocyclic carbocyclic groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopento-1-enyl, 1-cyclopento-2-enyl, 1-cyclopento-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, indenyl, indanyl, 1,2-dihydronaphthalene, and 1,2,3,4-tetrahydronaphthyl. The carbocyclyl group may be independently substituted with one or more substituents described herein.

[0019]

[0019] "Aryl" is derived by removing one hydrogen atom from a single carbon atom of a hydrophilic aromatic ring system, resulting in 6 to 20 carbon atoms (C6-C6-C6). 20 This refers to a monovalent aromatic hydrocarbon radical. Some aryl groups are represented as "Ar" in exemplary structures. Typical aryl groups include, but are not limited to, radicals derived from benzene (phenyl), substituted benzenes, naphthalenes, anthracenes, and others. The aryl group may be independently substituted with one or more substituents as described herein.

[0020]

[0020] The terms “heterocyclic,” “heterocyclyl,” and “heterocyclic ring” are used interchangeably herein and refer to a saturated or partially unsaturated (i.e., having one or more double and / or triple bonds in the ring) carbocyclic group consisting of 3 to about 20 ring atoms, wherein at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus, and sulfur, and the remaining ring atoms are C, wherein one or more ring atoms may be independently substituted with one or more substituents as described herein. The heterocyclic ring may be a monocyclic ring having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected from N, O, P, and S), or a dicyclic ring having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P, and S), such as a bicyclo[4,5], [5,5], [5,6], or [6,6] system. Heterocyclic compounds are described in Paquette, Leo A.; “Principles of Modern Heterocyclic Chemistry” (WABenjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J.Am.Chem.Soc (1960) 82:5566. “Heterocyclyl” also includes radicals in which a heterocyclic radical is fused with a saturated, partially unsaturated ring, or an aromatic carbocyclic or heterocyclic ring.Examples of heterocyclic rings include morpholine-4-yl, piperidine-1-yl, piperazinyl, piperazine-4-yl-2-one, piperazine-4-yl-3-one, pyrrolidine-1-yl, thiomorpholine-4-yl, S-dioxothiomorpholine-4-yl, azocan-1-yl, azetidine-1-yl, octahydropyrido[1,2-a]pyrazine-2-yl, [1,4]diazepan-1-yl, pyrrolidinyl, tetrahydrofuranil, dihydrofuranil, tetrahydrothienyl, tetrahydropyranil, dihydropyranil, tetrahydrothiopyranil, piperidino, morpholino, thiomorpholino, thiooxanil, piperazinyl, homopiperazinyl, and Examples include, but are not limited to, zetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinylimidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indollyquinolidinyl, and N-pyridylurea. The spiro portion is also included in the scope of this definition. Examples of heterocyclic groups in which two ring atoms are substituted with an oxo (=O) moiety are pyrimidinoni and 1,1-dioxo-thiomorpholinyl. Heterocyclic groups as used herein may be independently substituted with one or more substituents as described herein.

[0021]

[0021] The term "heteroaryl" refers to a monovalent aromatic group of a 5, 6, or 7 membered ring, and includes a fused ring system of 5 to 20 atoms (at least one of which is aromatic) containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include pyridinyl (e.g., 2-hydroxypyridinyl), imidazolyl, imidazopyridinyl, 1-methyl-1H-benzo[d]imidazole, [1,2,4]triazolo[1,5-a]pyridine, pyrimidinyl (e.g., 4-hydroxypyridinyl), pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, These include isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, synnolinyl, indazolyl, indolidinyl, phthalazinyl, pyridadinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, thiadiazolyl, flazanyl, benzoflazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthilidinyl, and phlopyridinyl. The heteroaryl group may be independently substituted with one or more substituents described herein.

[0022]

[0022] The heterocyclic or heteroaryl group may, if possible, be bonded to carbon (bonded to carbon) or nitrogen (bonded to nitrogen). For example, but not limited to, carbon-bonded heterocyclic or heteroaryl groups are bonded at positions 2, 3, 4, 5, or 6 of pyridine, positions 3, 4, 5, or 6 of pyridazine, positions 2, 4, 5, or 6 of pyrimidine, positions 2, 3, 5, or 6 of pyrazine, positions 2, 3, 5, or 5 of furan, tetrahydrofuran, thiofuran, thiophene, pyrrole, or tetrahydropyrrole, positions 2, 3, 4, or 5 of oxazole, imidazole, or thiazole, positions 3, 4, or 5 of isoxazole, pyrazole, or isothiazole, positions 2 or 3 of aziridine, positions 2, 3, or 4 of azetidine, positions 2, 3, 4, 5, 6, 7, or 8 of quinoline, or positions 1, 3, 4, 5, 6, 7, or 8 of isoquinoline.

[0023]

[0023] For example, though not limited to, nitrogen-bonded heterocycles or heteroaryls are bonded at position 1 of aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of isoindole or isoindoline, position 4 of morpholine, and position 9 of carbazole or β-carbolin.

[0024]

[0024] The term "oxo" refers to "=O".

[0025]

[0025] The “patient,” “individual,” or “subject” is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans, and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the patient, individual, or subject is a human. In some embodiments, the patient may be a “cancer patient,” i.e., a patient who has or is at risk of having one or more symptoms of cancer.

[0026]

[0026] "Cancer" and "cancerous" refer to or describe a physiological condition in mammals that is typically characterized by uncontrolled cell growth / proliferation. "Tumor" includes one or more cancer cells.

[0027]

[0027] As used herein, “treatment” (and its grammatical variations such as “treat” or “treating”) refers to a clinical intervention that attempts to alter the natural course of the individual being treated, and may be performed for preventive purposes or in the course of clinicopathology. Desired effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, reducing the direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and achieving remission or improving prognosis. In some embodiments, the compounds and compositions of the subject matter described herein are used to delay the progression of disease or to slow the progression of disease. In one embodiment, treatment is performed solely for preventive purposes. In another embodiment, treatment is performed only during the course of the clinical condition (i.e., not for preventive purposes). In yet another embodiment, treatment is performed both during the course of the clinical condition and for preventive purposes.

[0028]

[0028] The term “effective” is used to describe the amount of a compound, composition, or component that, when used in the context of its intended use, achieves a desired therapeutic or preventive outcome. The term “effective” encompasses other terms of effective amount or effective concentration, including therapeutic effective amount, as used otherwise in this application. As used herein, “therapeutic effective amount” means any amount that, compared to a corresponding subject not receiving such amount, results in the treatment of a disease, disorder, or side effect, or a reduction in the rate of progression of a disease or disorder. The term also includes, within its scope, amounts effective to enhance normal physiological function. In the case of therapeutic use, a therapeutic effective amount of the compounds of this disclosure, and their stereoisomers or tautomers, or any pharmaceutically acceptable salts thereof, may be administered as raw chemicals. In addition, active ingredients may be presented as pharmaceutically acceptable compositions.

[0029]

[0029] The term “pharmaceutical preparation” or “pharmaceutical composition” refers to a preparation in which the biological activity of the active ingredient contained herein is effective, and which does not contain any ingredients that are toxic to an extent that would be unacceptable to the subject to whom the preparation is administered.

[0030]

[0030] "Pharmacologically acceptable additives" refer to components of a pharmaceutical preparation other than the active ingredient that are nontoxic to the target. Pharmaceutically acceptable additives include, but are not limited to, buffers, carriers, stabilizers, or preservatives.

[0031]

[0031] As used herein, the term “pharmaceutically acceptable salt” refers to a pharmaceutically acceptable organic or inorganic salt of a molecule. Exemplary salts include, but are not limited to, sulfates, citrates, acetates, oxalates, chlorides, bromides, iodides, nitrates, bisulfates, phosphates, acidic phosphates, isonicotinates, lactates, salicylates, acidic citrates, tartrates, oleates, tannates, pantothenates, bicarbonate tartrates, ascorbicates, succinates, maleates, gentisinates, fumarates, glucons, glucurons, sugarates, formates, benzoates, glutamates, methanesulfons, ethanesulfons, benzenesulfons, p-toluenesulfons, and pamoates (i.e., 1,1'-methylenebis-(2-hydroxy-3-naphthonate)). A pharmaceutically acceptable salt may contain other molecules, such as acetate ions, succinate ions, or other counterions. The counterion may be any organic or inorganic site that stabilizes the charge of the parent compound. Furthermore, a pharmaceutically acceptable salt may have multiple charged atoms in its structure. If multiple charged atoms are part of the pharmaceutically acceptable salt, it may have multiple counterions. Therefore, a pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counterions.

[0032]

[0032] Other pharmaceutically unacceptable salts may be useful in the preparation of the compounds described herein, and these should be considered to form further embodiments of the subject matter. These salts, such as oxalates or trifluoroacetates, are not pharmaceutically acceptable in themselves, but may be useful in the preparation of salts that are useful as intermediates in obtaining the compounds described herein and their pharmaceutically acceptable salts.

[0033]

[0033] The term "stereoisomer" refers to compounds that have the same chemical structure but differ in terms of the spatial arrangement of atoms or groups.

[0034]

[0034] The term "diastereomer" refers to stereoisomers having two or more chiral centers, wherein the molecules are not mirror images of each other. Diastereomers have different physical properties, such as melting point, boiling point, spectral properties, and reactivity. Mixtures of diastereomers may be separated under high-resolution analytical procedures such as electrophoresis and chromatography.

[0035]

[0035] "Optical isomers" refer to two stereoisomers of a compound that are mirror images of each other and cannot be superimposed.

[0036]

[0036] The stereochemical definitions and conventions used herein follow SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., StereoChemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing optically active compounds, the prefixes D and L, or R and S, are used to indicate the absolute configuration of the molecule around one or more chiral centers. The prefixes d and l or (+) and (-) are used to indicate the sign of the rotation of plane-polarized light by the compound, where (-) or 1 means that the compound is levorotatory. Compounds with the prefix (+) or d are dextrorotatory. In a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Furthermore, certain stereoisomers are sometimes called enantiomers, and mixtures of such isomers are often called enantiomer mixtures. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which can occur when there is no stereoselectivity or stereospecificity in a chemical reaction or method. The terms "racemic mixture" and "racemate" refer to equimolar mixtures of two enantiomer species that are not optically active.

[0037]

[0037] As used herein, the term “compound” means any specific chemical compound disclosed herein unless otherwise indicated, including tautomers, positional isomers, geometric isomers, and, where applicable, stereoisomers, including its optical isomers (enantiomers) and other stereoisomers (diastereomers), and, where applicable in context, its pharmaceutically acceptable salts and derivatives (including prodrug forms). In context, the term “compound” generally means a single compound, but may also include other compounds such as stereoisomers, positional isomers, and / or optical isomers (including racemic mixtures), as well as specific enantiomers or enantio-enriched mixtures of the disclosed compound. The term also means, in context, a prodrug form of a compound that has been modified to facilitate administration and delivery to the active site. Note that in the description of the compound, in particular, numerous substituents and variables associated with the compound will be described. Those skilled in the art will understand that the molecules described herein are generally stable compounds, as described below. [ka] When shown, both double bonds and single bonds are presented within the context of the compound being shown. Crossed double bond ( [ka] Where indicated, both E and Z configurations are shown within the context of the compound shown, and the compound may contain an E isomer, a Z isomer, or a mixture of both E and Z isomers.

[0038]

[0038] In certain embodiments disclosed herein, certain groups (e.g., alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl) are described as “substituted.” In some such embodiments, the “substituted” group may be substituted with one, two, three, four, five, or more substituents, as shown herein. In certain embodiments, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo (i.e., halogen), haloalkyl, oxo, OH, CN, -O-alkyl, S-alkyl, NH-alkyl, N(alkyl)2, O-cycloalkyl, S-cycloalkyl, NH-cycloalkyl, N(cycloalkyl)2, N(cycloalkyl)(alkyl), NH2, SH, SO2-alkyl, P(O)(O-alkyl)(alkyl), P(O)(O-alkyl)2, Si(OH)3, Si(alkyl It may be substituted with one or more substitutions independently selected from, but not limited to, 3, Si(OH)(alkyl)2, CO-alkyl, CO2H, NO2, SF5, SO2NH-alkyl, SO2N(alkyl)2, SONH-alkyl, SON(alkyl)2, CONH-alkyl, CON(alkyl)2, N(alkyl)CONH(alkyl), N(alkyl)CON(alkyl)2, NHCONH(alkyl), NHCON(alkyl)2, NHCONH2, N(alkyl)SO2NH(alkyl), N(alkyl)SO2N(alkyl)2, NHSO2NH(alkyl), NHSO2N(alkyl)2, and NHSO2NH2.

[0039]

[0039] When a range of values ​​is provided, it is understood that each intermediate value between the upper and lower limits of that range, up to one-tenth of the unit of the lower limit, and any other stated or intermediate values ​​within that stated range are included in this disclosure, unless the context otherwise clearly indicates (for example, in the case of a group containing many carbon atoms, where the number of each carbon that falls within that range is provided). The upper and lower limits of these smaller ranges, which may be independently included in smaller ranges, are also included in this disclosure, subject to any particularly excluded limits within the stated range. If the stated range includes one or both limits, the range excluding one or both of those included limits is also included in this disclosure.

[0040]

[0040] The articles “a” and “an” as used herein and in the appended claims are used herein to mean one or more (i.e., at least one) grammatical objects of the article, unless the context otherwise clearly indicates. For example, “element” means one or more elements.

[0041]

[0041] In the claims, as in the specification described above, transitional phrases such as “comprising / including,” “carrying / having,” “containing,” “involving,” “holding,” and “composed of” should be understood as open-ended, meaning that they include but are not limited to them. Only the transitional phrases “consisting of” and “consisting essentially of” must be closed or semi-closed transitional phrases, respectively, as described in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

[0042]

[0042] In any particular method described herein that includes multiple steps or actions, the order of the steps or actions of the method is not necessarily limited to the order in which the steps or actions of the method are described, unless the context indicates otherwise.

[0043] II. Compounds

[0043] In one embodiment, the compound of formula (I) is provided herein: [ka] or its stereoisomer or tautomer, or any of the aforementioned pharmaceutically acceptable salts [in the formula, I)L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 teeth, i) One or more R s It may be replaced with -OC 6-20 It is aryl; here, R s Each instance is independently a halo; ii) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl; iii) A 5-20 member heteroaryl, where R 2 The 5-20 member heteroaryls are one or more R s It is replaced by; here, R s Each appearance is independent of the others, Haro, C 1-12 It is alkyl; iv) One or more R s Even if replaced by C 6-20 It is a cycloalkyl; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl, or II)L2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 teeth, i)-L 3 -C 6-20 It is aryl; here, L 3 is O or C(O)NH; -L 3 -C 6-20 Ariel's C 6-20 A aryl is one or more R s It may also be replaced with, where R s Each appearance is independent of Haro C 1-6 It is alkyl; ii) One or more R s Even if replaced by C 4-20 It is a cycloalkyl, where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl; iii) One or more R s Even if replaced by C 6-20 It is aryl; here, R s Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R s The 5-20 member heteroaryls have one or more ring atoms independently selected from N and O; R s The 5-20 member heteroaryls are one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 1-6 It is alkyl; iv) One or more R sIt is a 5-20 member heteroaryl which may be substituted with; where R s Each instance independently produces a halo, amine, and C. 1-6 Alkyl, or C 6-20 It is an allele; R s C 6-20 A aryl is one or more R t It may also be replaced with; here, R t Each instance is independently a halo; v) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Aryl, or C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; R t Each occurrence is independent of C 6-20 It is Ariel, R s C 6-20 A aryl is one or more R u It may also be replaced with; R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. That is the case.

[0044]

[0044] In some embodiments, the compound of formula (I) is the compound of formula (Ia): [ka] or its stereoisomer or tautomer, or any of the aforementioned pharmaceutically acceptable salts [in the formula, L 2 is a combination or C 1-12 It is alkyl; R 2 teeth, i) One or more R sIt may be replaced with -OC 6-20 It is aryl; here, R s Each instance is independently a halo; ii) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl; iii) A 5-20 member heteroaryl, where R 2 The 5-20 member heteroaryls are one or more R s It is replaced by; here, R s Each appearance is independent of whether it is a halo or C. 1-12 It is alkyl; iv) One or more R s Even if replaced by C 6-20 It is a cycloalkyl; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl. That is the case.

[0045]

[0045] In some embodiments, the compound of formula (I) is the compound of formula (Ib): [ka] or its stereoisomer or tautomer, or any of the aforementioned pharmaceutically acceptable salts [in the formula, L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 teeth, i)-L 3 -C 6-20 It is aryl; here, L 3is O or C(O)NH; -L 3 -C 6-20 Ariel's C 6-20 A aryl is one or more R s It may also be replaced with, where R s Each appearance is independent of Haro C 1-6 It is alkyl; ii) One or more R s Even if replaced by C 4-20 It is a cycloalkyl, where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl; iii) One or more R s Even if replaced by C 6-20 It is aryl; here, R s Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R s The 5-20 member heteroaryls have one or more ring atoms independently selected from N and O; R s The 5-20 member heteroaryls are one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 1-6 It is alkyl; iv) One or more R s It is a 5-20 member heteroaryl which may be substituted with; where R s Each instance independently produces a halo, amine, and C. 1-6 Alkyl, or C 6-20 It is an allele; R s C 6-20 A aryl is one or more R t It may also be replaced with; here, R t Each instance is independently a halo; v) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C.6-20 Aryl, or C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; R t Each occurrence is independent of C 6-20 It is Ariel, R s C 6-20 A aryl is one or more R u It may also be replaced with; R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. That is the case.

[0046]

[0046] In some embodiments, the compound of formula (I) or formula (Ia) is the compound of formula (Ia-1) or (Ia-2): [ka] In the formula, L 2 and R 2 This is as defined for formula (I). In some embodiments, the compound is the compound of formula (Ia-1). In some embodiments, the compound is the compound of formula (Ia-2).

[0047]

[0047] In some embodiments, the compound of formula (I) or formula (Ib) is the compound of formula (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), or (Ib-9): [ka] And in the formula, L 1 and R 1This is as defined for formula (I). In some embodiments, the compound is the compound of formula (Ib-1). In some embodiments, the compound is the compound of formula (Ib-2). In some embodiments, the compound is the compound of formula (Ib-3). In some embodiments, the compound is the compound of formula (Ib-4). In some embodiments, the compound is the compound of formula (Ib-5). In some embodiments, the compound is the compound of formula (Ib-6). In some embodiments, the compound is the compound of formula (Ib-7). In some embodiments, the compound is the compound of formula (Ib-8). In some embodiments, the compound is the compound of formula (Ib-9).

[0048]

[0048] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 is one or more R s It may be replaced with -OC 6-20 It is aryl, and here, R s Each instance of its appearance is independently a halo. That is the case.

[0049]

[0049] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing, wherein R 2 R is a compound, stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof, which may be a -O-C6 aryl substituted with one or more halos. In some such embodiments, R 2R is a -O-C6 aryl which may be substituted with one or more fluoropolymers. In some such embodiments, R 2 It is a -O-C6 aryl compound substituted with one fluoropolymer.

[0050]

[0050] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 is one or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl. That is the case.

[0051]

[0051] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is one or more -C(O)OC 1-6 A compound that is a six-membered heterocyclyl which may be substituted with alkyl, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof. In some embodiments, R 2 is a six-membered heterocycline which may be substituted with one or more -C(O)O-CH3 groups. In some embodiments, R 2 is a 6-membered heterocycline substituted with one -C(O)O-CH3. In some embodiments, R 2 is one or more -C(O)OC 1-6It is a 6-membered heterocycline containing 1 to 3 N heteroatoms, which may be substituted with alkyl groups. In some embodiments, R 2 R is a 6-membered heterocycline containing 1 to 3 N heteroatoms, which may be substituted with one or more -C(O)O-CH3 groups. In some embodiments, R 2 It is a 6-membered heterocycline containing 1 to 3 N heteroatoms, substituted with one -C(O)O-CH3. In some embodiments, R 2 is one or more -C(O)OC 1-6 It may be substituted with alkyl. [ka] In some embodiments, R 2 It may be substituted with one or more -C(O)O-CH3 groups. [ka] That is the case.

[0052]

[0052] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salts thereof, wherein, L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 R is a 5-20 member heteroaryl, where R 2 The 5-20 member heteroaryls are one or more R s It is replaced by; here, R s Each appearance is independent of whether it is a halo or C. 1-12 It is alkyl. A compound, or a stereoisomer or tautomer thereof, or any of the aforementioned pharmaceutically acceptable salts.

[0053]

[0053] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salts thereof, wherein R 2 is one or more R s It is a 6-9 member heteroaryl substituted with; where R s Each appearance is independent of whether it is a halo or C. 1-12 A compound that is alkyl, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof. In some embodiments, R 2 is one or more halos or C 1-12 It is a six-membered heteroaryl substituted with alkyl. In some embodiments, R 2 is a 6-membered heteroaryl substituted with one or more fluoro or C1 alkyl groups. In some embodiments, R 2 is one or more halos or C 1-12 It is a 6-membered heteroaryl compound containing 1 to 3 N heteroatoms, substituted with alkyl. In some embodiments, R 2 is one or more halos or C 1-12 Alkyl-substituted [ka] In some embodiments, R 2 is substituted with one or more fluoro or C1 alkyl groups. [ka] In some embodiments, R 2 is one or more halos or C 1-12 It is a 9-membered heteroaryl substituted with alkyl. In some embodiments, R 2 is a 9-membered heteroaryl substituted with one or more C1 alkyl groups. In some embodiments, R 2 is one or more halos or C 1-12It is a 9-membered heteroaryl compound containing 1 to 3 N heteroatoms, substituted with alkyl. In some embodiments, R 2 is one or more halos or C 1-12 Alkyl-substituted [ka] In some embodiments, R 2 is substituted with one or more C1 alkyl groups. [ka] That is the case.

[0054]

[0054] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 is one or more R s Even if replaced by C 6-20 It is a cycloalkyl; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl. That is the case.

[0055]

[0055] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is one or more -C(O)OC 1-6 A compound that is a C6 cycloalkyl group which may be substituted with alkyl, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof. In some embodiments, R 2is a C6 cycloalkyl which may be substituted with one or more -C(O)O-CH3 groups. In some embodiments, R 2 It is a C6 cycloalkyl group substituted with one -C(O)O-CH3 group.

[0056]

[0056] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 is -L 3 -C 6-20 It is aryl; here, L 3 is O or C(O)NH; -L 3 -C 6-20 Ariel's C 6-20 A aryl is one or more R s It may also be replaced with, where R s Each appearance is independent of Haro C 1-6 It is alkyl. That is the case.

[0057]

[0057] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is -L 3 -C6 aryl, L 3 is O or C(O)NH, and -L 3- The C6 aryl of the C6 aryl independently produces one or more halo C at each occurrence. 1-6 A compound, which may be substituted with alkyl, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof as described above. In some embodiments, L 3 In some embodiments, L 3 is C(O)NH. In some embodiments, R 1 is, -L 3 -C6 aryl, where L 3 is O or C(O)NH, and -L 3 -The C6 aryl in C6 aryl may be substituted with one or more halo-C1 alkyl groups. In some embodiments, R 1 is, -L 3 -C6 aryl, where L 3 is O or C(O)NH, and -L 3 -The C6 aryl in C6 aryl may be substituted with one or more fluoroC1 alkyl groups. In some embodiments, R 1 is, -L 3 -C6 aryl, where L 3 is O or C(O)NH, and -L 3 -The C6 aryl in the C6 aryl may be replaced with one or more -CF3. In some embodiments, R 1 is, -L 3 -C6 aryl, where L 3 is O or C(O)NH, and -L 3 -The C6 aryl group of the C6 aryl group is replaced by one -CF3 group. In some embodiments, R 1 is, -L 3 -C6 aryl, where L 3 is O or C(O)NH, and -L 3 -The C6 aryl group in the C6 aryl group has been replaced.

[0058]

[0058] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, C 1-12 Alkyl L 1 is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 is one or more R s Even if replaced by C 4-20 It is a cycloalkyl; where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl. That is the case.

[0059]

[0059] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salts thereof, wherein R 1 is one or more R s Even if replaced by C 6-11 It is a cycloalkyl; where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 A compound that is alkyl, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof. In some embodiments, R 1 is one or more R s A C6 cycloalkyl which may be substituted with; where R sEach occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl. In some such embodiments, R s Each occurrence independently produces a 9-membered heteroaryl or S(O)C 1-6 It is alkyl. In some such embodiments, R s Each instance occurs independently. [ka] Or it is S(O)CH2CH3. In some embodiments, R 1 is one or more R s A C9 cycloalkyl which may be substituted with; where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl. In some such embodiments, R s In some such embodiments, R s is chloro. In some embodiments, R 1 is one or more R s It may be replaced with [ka] And here, R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl. In some such embodiments, R s In some such embodiments, R s is chloro. In some embodiments, R 1 is one or more R s Even if replaced by C 11 It is a cycloalkyl; where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl. In some such embodiments, R sIn some such embodiments, R s In each instance, it is independently bromo. In some embodiments, R 1 is one or more R s It may be replaced with [ka] And here, R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl. In some such embodiments, R s In some such embodiments, R s Each instance of its appearance is independently a Bromo.

[0060]

[0060] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 Alkyl; L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 is one or more R s Even if replaced by C 6-20 It is aryl; here, R s Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R s The 5-20 member heteroaryls have one or more ring atoms independently selected from N and O; R sThe 5-20 member heteroaryls are one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 1-6 It is alkyl. That is the case.

[0061]

[0061] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salts thereof, wherein R 1 is one or more R s A C6 aryl which may be substituted with; where R s Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl, and R s The 5-20 member heteroaryls have one or more ring atoms independently selected from N and O; R s The 5-20 member heteroaryls are one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 1-6 A compound that is alkyl, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof. In some embodiments, R 1 is one or more R s A C6 aryl which may be substituted with; where R s Each instance is independently fluoro, bromo, or cyano.

[0062]

[0062] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12Alkyl may be substituted with one or more R e ; wherein R e is, independently at each occurrence, C 1-6 alkyl or hydroxy C 1-6 alkyl; R 1 is 5-20 membered heteroaryl which may be substituted with one or more R s ; wherein R s is, independently at each occurrence, halo, amino, C 1-6 alkyl or C 6-20 aryl; R s of C 6-20 aryl may be substituted with one or more R t ; wherein R t is, independently at each occurrence, halo] .

[0063]

[0063] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is 5-9 membered heteroaryl which may be substituted with one or more R s ; wherein R s is, independently at each occurrence, halo, amino, C 1-6 alkyl, or C 6-20 aryl; wherein C s of R 6-20 aryl may be substituted with one or more R t ; wherein R t is, independently at each occurrence, halo, which is the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, R 1 is 5-membered heteroaryl which may be substituted with one or more R s ; wherein R s is, independently at each occurrence, halo, amino, C 1-6 alkyl, or C 6-20It is aryl; here, R s C 6-20 A aryl is one or more R t It may also be replaced with; here, R t In some such embodiments, R s Each occurrence is independent of C 1-2 It is an alkyl or C6 aryl; where R s The C6 aryl is one or more R t It may also be replaced with; here, R t In some such embodiments, R s C 1-2 Alkyl, [ka] In some embodiments, R 1 is one or more R s It may be replaced with [ka] And here R s Each instance independently produces a halo, amine, and C. 1-6 Alkyl, or C 6-20 It is aryl; here, R s C 6-20 A aryl is one or more R t It may also be replaced with; here, R t In some such embodiments, R s Each occurrence is independent of C 1-2 It is an alkyl or C6 aryl; where R s The C6 aryl is one or more R t It may also be replaced with; here, R t In some such embodiments, R s C 1-2 Alkyl, [ka] . In some embodiments, R 1 is 9-membered heteroaryl optionally substituted with one or more R s ; wherein R s at each occurrence is independently halo, amine, C 1-6 alkyl, or C 6-20 aryl; wherein the C s aryl of R 6-20 is optionally substituted with one or more R t ; wherein R t at each occurrence is independently halo. In some embodiments, R 1 is 9-membered heteroaryl optionally substituted with one or more R s ; wherein R s at each occurrence is independently halo or amine. In some embodiments, R 1 is optionally substituted with one or more R s

Chemical Formula

[0064]

[0064] In some embodiments, provided herein is a compound of Formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; wherein the C 1 alkyl of L 1-12 alkyl is optionally substituted with one or more R e ; wherein R e at each occurrence is independently C 1-6 alkyl or hydroxy C 1-6 alkyl; R 1 ​is one or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Aryl, or C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 6-20 It is Ariel, R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. That is the case.

[0065]

[0065] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is one or more R s A 4-10 member heterocyclyl which may be substituted with; where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Ariel, C 1-6 It is alkyl; here, R s C 1-6 Alkyl is one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 6-20 It is aryl; R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u When it appears, it independently becomes a halo or C 1-6A compound that is alkyl, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above.

[0066] In some embodiments, R 1 is one or more R s It is a four-membered heterocyclyl which may be substituted with, where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Ariel, C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 6-20 It is aryl; R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. In some embodiments, R 1 is one or more R s It is a four-membered heterocyclyl which may be substituted with, where R s Each occurrence independently generates one or more R t Hydroxyl, 5-20 member heteroaryl, or C may be substituted with 1-6 It is alkyl; R t Each occurrence is independent of C 6-20 It is an arrow. In some such embodiments, R s Each instance independently produces a hydroxyl, pyridine, or one or more R compounds. t A C1 alkyl which may be substituted with; where R t In each occurrence, it is independently a C6 aryl. In some embodiments, R 1 is one or more R s It may be replaced with [ka] And here, R s Each instance independently produces a hydroxyl, a 5-20 membered heteroaryl, or one or more R compounds. t Even if replaced by C 1-6 It is alkyl; here, R t Each occurrence is independent of C 6-20 It is an aryl group. In some such embodiments, Rs is a C1 alkyl group which may be independently substituted with hydroxyl, pyridine, or one or more Rt groups in each occurrence; where Rt is independently a C6 aryl group in each occurrence.

[0067]

[0067] In some embodiments, R 1 is one or more R s It is a 5-membered heterocyclyl which may be substituted with, where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Ariel, C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 6-20 It is aryl; R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. In some such embodiments, R 1 is one or more R s It is a 5-membered heterocyclyl which may be substituted with R, where R s C 6-20 It is aryl; R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. In some such embodiments, Rs is one or more R u A C6 aryl which may be substituted with; where R u In each instance, R is independently C1 alkyl or chloro. In some embodiments, R 1 is one or more R s It may be replaced with [ka] And here R s C 6-20 It is aryl; R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. In some such embodiments, R s is one or more R u A C6 aryl which may be substituted with; where R u Each instance of appearance is independently either C1 alkyl or chloro.

[0068]

[0068] In some embodiments, R 1 is one or more R s It is a 10-membered heterocyclyl which may be substituted with, where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Ariel, C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 6-20 It is aryl; R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. In some embodiments, R1 is one or more R s A 10-membered heterocyclyl which may be substituted with; where R s Each occurrence is independent of oxo or C. 6-20 It is an arrow. In some such embodiments, R s In each instance, it is independently either oxo or C6 aryl. In some embodiments, R 1 is one or more R s A 10-membered heterocycline comprising one or more heteroatoms selected from the group consisting of O and S, which may be substituted with R, where R s Each occurrence is independent of oxo or C. 6-20 It is an arrow. In some such embodiments, R s In each instance, it is independently either oxo or C6 aryl. In some embodiments, R 1 is one or more R s It may be replaced with [ka] And here, R s Each occurrence is independent of oxo or C. 6-20 It is an arrow. In some such embodiments, R s Each instance is independently either oxo or C6 aryl.

[0069]

[0069] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 teeth, [ka] Selected from the group consisting of [ That is the case.

[0070]

[0070] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing, wherein L 2 This refers to a compound that is a bond or -CH2-, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt of any of the above.

[0071]

[0071] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 1 -R 1 It is methyl; L 2 is a bond or -CH2-; R 2 teeth, [ka] Selected from the group consisting of [ That is the case.

[0072]

[0072] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 1 -R 1 It is methyl; L 2 is a combination; R 2 teeth, [ka] Selected from the group consisting of [ That is the case.

[0073]

[0073] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 1 -R 1 It is methyl; L 2 is -CH2-; R 2 teeth, [ka] Selected from the group consisting of [ That is the case.

[0074]

[0074] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It is also fine if it is replaced with;R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 teeth, [ka] [ka] Selected from the group consisting of [ That is the case.

[0075]

[0075] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing, wherein L 1 This refers to a compound selected from the group consisting of a bond, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2-, and -CH(CH2CH3)CH2-, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt of any of the above.

[0076]

[0076] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the foregoing [wherein, L 2 -R 2 It is cyclopropyl; L 1 It is selected from the group consisting of a bond, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2-, and -CH(CH2CH3)CH2-; R 1 teeth, [ka] Selected from the group consisting of: That is the case.

[0077]

[0077] In some embodiments, the provided compounds of formula (I), or stereoisomers or tautomers thereof, or any of the pharmaceutically acceptable salts described above [wherein, L 2 -R 2 It is cyclopropyl; L 1 is a combination; R 1 teeth, [ka] Selected from the group consisting of: That is the case.

[0078]

[0078] In some embodiments, the provided compounds of formula (I), or stereoisomers or tautomers thereof, or any of the pharmaceutically acceptable salts described above [wherein, L 2 -R 2 It is cyclopropyl; L 1 It is selected from the group consisting of -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2-, and -CH(CH2CH3)CH2-; R 1 teeth, [ka] Selected from the group consisting of: That is the case.

[0079]

[0079] In some embodiments, the provided compounds of formula (I), or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt thereof, wherein the compound is [ka] [ka] A compound, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof, selected from the group consisting of the above.

[0080]

[0080] In some embodiments, the provided is a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound is [ka] [ka] A compound or a pharmaceutically acceptable salt thereof, selected from the following.

[0081]

[0081] In another embodiment, a compound of formula (II) is provided: [ka] or its stereoisomer or tautomer, or any of the aforementioned pharmaceutically acceptable [in the formula, I)L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 teeth, i) One or more R s It may be replaced with -OC 6-20 It is aryl; here, R s Each instance is independently a halo; ii) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl; iii) A 5-20 member heteroaryl, where R 2 The 5-20 member heteroaryls are one or more R s It is replaced by; here, R s Each appearance is independent of whether it is a halo or C. 1-12 It is alkyl; iv) One or more R s Even if replaced by C 6-20 It is a cycloalkyl; where R s Each occurrence is independently -C(O)OC 1-6 It is alkyl; v)-N(CH3)-C 6-20 It is an allele; vi) One or more R s Even if replaced with -C6-20 It is aryl, and here, R s Each occurrence is independent of C 1-6 It is a haloalkyl; or II)L 2 -R 2 It is cyclopropyl; L 1 is a combination or C 1-12 It is alkyl; here, L 1 C 1-12 Alkyl is one or more R e It may also be replaced with; here, R e Each occurrence is independent of C 1-6 Alkyl or hydroxyl C 1-6 It is alkyl; R 1 teeth, i)-L 3 -C 6-20 It is aryl; here, L 3 is O or C(O)NH; -L 3 -C 6-20 Ariel's C 6-20 A aryl is one or more R s It may also be replaced with, where R s Each appearance is independent of Haro C 1-6 It is alkyl; ii) One or more R s Even if replaced by C 4-20 It is a cycloalkyl, where R s Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. 1-6 It is alkyl; iii) One or more R s Even if replaced by C 6-20 It is aryl; here, R s Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R s The 5-20 member heteroaryls have one or more ring atoms independently selected from N and O; R s The 5-20 member heteroaryls are one or more R tIt may also be replaced with; here, R t Each occurrence is independent of C 1-6 It is alkyl; iv) One or more R s It is a 5-20 member heteroaryl which may be substituted with; where R s Each instance independently produces a halo, amine, and C. 1-6 Alkyl, or C 6-20 It is an allele; R s C 6-20 A aryl is one or more R t It may also be replaced with; here, R t Each occurrence is independently a halo; or v) One or more R s A 4-20 member heterocyclyl which may be substituted with; where R s Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. 6-20 Aryl, or C 1-6 It is alkyl; R s C 1-6 Alkyl is one or more R t It may also be replaced with; here, R t Each occurrence is independent of C 6-20 It is Ariel, R s C 6-20 A aryl is one or more R u It may also be replaced with; here, R u Each appearance is independent of whether it is a halo or C. 1-6 It is alkyl. That is the case.

[0082]

[0082] It should be understood that any method of preparing or using the compound of formula (I) also applies to the compound of formula (II).

[0083]

[0083] In some embodiments, provided herein are compounds of formula (II) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the above [wherein, L 1 -R 1 It is methyl; L 2 is a combination or C 1-12 It is alkyl; R 2 teeth, [ka] Selected from the group consisting of [ That is the case.

[0084]

[0084] In some embodiments, provided herein are compounds of formula (II) or any applicable subformula thereof, or stereoisomers or tautomers thereof, or any pharmaceutically acceptable salt of any of the above-mentioned formulas [wherein, L 2 -R 2 It is cyclopropyl; L 1 It is selected from the group consisting of a bond, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2-, and -CH(CH2CH3)CH2-; R 1 teeth, [ka] Selected from the group consisting of: That is the case.

[0085]

[0085] The compounds described herein include the compounds of Table 1-A, Table 1-B, or Table 1-C, or their stereoisomers or tautomers, or any of the pharmaceutically acceptable salts described herein. Table 1-A [Table 1-A-1]

Table 1-A-2

Table 1-A-3

Table 1-A-4

Table 1-A-5

Table 1-A-6

Table 1-A-7

Table 1-A-8

Table 1-A-9

Table 1-A-10

Table 1-A-11

Table 1-A-12

Table 1-A-13

Table 1-A-14

Table 1-A-15

Table 1-A-16

Table 1-A-17

Table 1-A-18

Table 1-A-19

Table 1-A-20

Table 1-A-21

Table 1-A-22

Table 1-A-23

Table 1-A-24

Table 1-A-25

Table 1-A-26

Table 1-A-27

Table 1-A-28

Table 1-A-29

Table 1-A-30

Table 1-A-31

Table 1-A-32

Table 1-A-33

Table 1-A-34

Table 1-A-35

Table 1-A-36

Table 1-A-37

Table 1-A-38

Table 1-A-39

Table 1-A-40

Table 1-A-41

Table 1-A-42

Table 1-A-43

Table 1-A-44

Table 1-A-45

Table 1-A-46

Table 1-A-47

Table 1-A-48

Table 1-A-49

Table 1-A-50

Table 1-A-51

Table 1-A-52

Table 1-A-53

Table 1-A-54

Table 1-A-55

Table 1-A-56

Table 1-A-57

Table 1-A-58

Table 1-A-59

Table 1-A-60

Table 1-A-61

Table 1-A-62

Table 1-A-63

Table 1-A-64

Table 1-A-65

Table 1-A-66

Table 1-A-67

Table 1-A-68

Table 1-A-69

Table 1-A-70

Table 1-A-71

Table 1-A-72

Table 1-A-73

Table 1-A-74

Table 1-A-75

Table 1-A-76

Table 1-A-77

Table 1-A-78

Table 1-A-79

Table 1-A-80

Table 1-A-81

Table 1-A-82

Table 1-A-83

Table 1-A-84

Table 1-A-85

Table 1-A-86

Table 1-A-87

Table 1-A-88

Table 1-A-89

Table 1-A-90

Table 1-A-91

Table 1-A-92

Table 1-A-93

Table 1-A-94

Table 1-A-95

Table 1-A-96

Table 1-A-97

Table 1-A-98

Table 1-A-99

Table 1-A-100

Table 1-A-101

Table 1-A-102

Table 1-A-103

Table 1-A-104

Table 1-A-105

Table 1-A-106

Table 1-A-107

Table 1-A-108

Table 1-A-109

Table 1-A-110

Table 1-A-111

Table 1-A-112

Table 1-A-113

Table 1-A-114

Table 1-A-115

Table 1-A-116

Table 1-A-117

Table 1-A-118

Table 1-A-119

Table 1-A-120

Table 1-A-121

Table 1-A-122

Table 1-A-123

Table 1-A-124

Table 1-A-125

Table 1-A-126

Table 1-A-127

Table 1-A-128

Table 1-A-129

Table 1-A-130

Table 1-A-131

Table 1-A-132

Table 1-A-133

Table 1-A-134

Table 1-A-135

Table 1-A-136

Table 1-A-137

Table 1-A-138

Table 1-A-139

Table 1-A-140

Table 1-A-141

Table 1-A-142

Table 1-A-143

Table 1-A-144

Table 1-A-145

Table 1-A-146

Table 1-A-147

Table 1-A-148

Table 1-A-149

Table 1-A-150

Table 1-A-151

Table 1-A-152

Table 1-A-153

Table 1-A-154

Table 1-A-155

Table 1-A-156

Table 1-A-157

Table 1-A-158

Table 1-A-159

Table 1-A-160

Table 1-A-161

Table 1-A-162

Table 1-A-163

Table 1-A-164

Table 1-A-165

Table 1-A-166

Table 1-A-167

Table 1-A-168

Table 1-A-169

Table 1-A-170

Table 1-A-171

Table 1-A-172

Table 1-A-173

Table 1-A-174

Table 1-A-175

Table 1-A-176

Table 1-A-177

Table 1-A-178

Table 1-A-179

Table 1-A-180

Table 1-A-181

Table 1-A-182

Table 1-A-183

Table 1-A-184

Table 1-A-185

Table 1-A-186

Table 1-A-187

Table 1-A-188

Table 1-A-189

Table 1-A-190

Table 1-A-191

Table 1-A-192

Table 1-A-193

Table 1-A-194

Table 1-A-195

Table 1-A-196

Table 1-A-197

Table 1-A-198

Table 1-A-199

Table 1-A-200

Table 1-A-201

Table 1-A-202

Table 1-A-203

Table 1-A-204

Table 1-A-205

Table 1-A-206

Table 1-A-207

Table 1-A-208

Table 1-A-209

Table 1-A-210

Table 1-A-211

Table 1-A-212

Table 1-A-213

Table 1-A-214

Table 1-A-215

Table 1-A-216

Table 1-A-217

Table 1-A-218

Table 1-A-219

Table 1-A-220

Table 1-A-221

Table 1-A-222

Table 1-A-223

Table 1-A-224

Table 1-A-225

Table 1-A-226

Table 1-A-227

Table 1-A-228

Table 1-A-229

Table 1-A-230

Table 1-A-231

Table 1-A-232

Table 1-A-233

Table 1-A-234

Table 1-A-235

Table 1-A-236

Table 1-A-237

Table 1-A-238

Table 1-A-239

Table 1-A-240

Table 1-A-241

Table 1-A-242

Table 1-A-243

Table 1-A-244

Table 1-A-245

Table 1-A-246

Table 1-A-247

Table 1-A-248

Table 1-A-249

Table 1-A-250

Table 1-A-251

Table 1-A-252

Table 1-A-253

Table 1-A-254

Table 1-A-255

Table 1-A-256

Table 1-A-257

Table 1-A-258

Table 1-A-259

Table 1-A-260

Table 1-A-261

Table 1-A-262

Table 1-A-263

Table 1-A-264

Table 1-A-265

Table 1-A-266

Table 1-A-267

Table 1-A-268

Table 1-A-269

Table 1-A-270

Table 1-A-271

Table 1-A-272

Table 1-A-273

Table 1-A-274

Table 1-A-275

Table 1-A-276

Table 1-A-277

Table 1-A-278

Table 1-A-279

Table 1-A-280

Table 1-A-281

Table 1-A-282

Table 1-A-283

Table 1-A-284

Table 1-A-285

Table 1-A-286

Table 1-A-287

Table 1-A-288

Table 1-A-289

Table 1-A-290

Table 1-A-291

Table 1-A-292

Table 1-A-293

Table 1-A-294

Table 1-A-295

Table 1-A-296

Table 1-A-297

Table 1-A-298

Table 1-A-299

Table 1-A-300

Table 1-A-301

Table 1-A-302

Table 1-A-303

Table 1-A-304

Table 1-A-305

Table 1-A-306

Table 1-A-307

Table 1-A-308

Table 1-A-309

Table 1-A-310

Table 1-A-311

Table 1-A-312

Table 1-A-313

Table 1-A-314

Table 1-A-315

Table 1-A-316

Table 1-A-317

Table 1-A-318

Table 1-A-319

Table 1-A-320

Table 1-A-321

Table 1-A-322

Table 1-A-323

Table 1-A-324

Table 1-B-1

Table 1-B-2

Table 1-B-3

Table 1-B-4

Table 1-B-5

Table 1-B-6

Table 1-B-7

Table 1-B-8

Table 1-B-9

Table 1-B-10

Table 1-B-11

Table 1-B-12

Table 1-B-13

Table 1-B-14

Table 1-B-15

Table 1-B-16

Table 1-B-17

Table 1-B-18

Table 1-B-19

Table 1-B-20

Table 1-B-21

Table 1-B-22

Table 1-B-23

Table 1-B-24

Table 1-B-25

Table 1-B-26

Table 1-B-27

Table 1-B-28

Table 1-B-29

Table 1-B-30

Table 1-B-31

Table 1-B-32

Table 1-B-33

Table 1-B-34

Table 1-B-35

Table 1-B-36

Table 1-B-37

Table 1-B-38

Table 1-B-39

Table 1-B-40

Table 1-B-41

Table 1-B-42

Table 1-B-43

Table 1-B-44

Table 1-B-45

Table 1-B-46

Table 1-B-47

Table 1-B-48

Table 1-B-49

Table 1-B-50

Table 1-B-51

Table 1-B-52

Table 1-B-53

Table 1-B-54

Table 1-B-55

Table 1-B-56

Table 1-B-57

Table 1-B-58

Table 1-B-59

Table 1-B-60

Table 1-B-61

Table 1-B-62

Table 1-B-63

Table 1-B-64

Table 1-B-65

Table 1-B-66

Table 1-B-67

Table 1-B-68

Table 1-B-69

Table 1-B-70

Table 1-B-71

Table 1-B-72

Table 1-B-73

Table 1-B-74

Table 1-B-75

Table 1-B-76

Table 1-B-77

Table 1-B-78

Table 1-B-79

Table 1-B-80

Table 1-B-81

Table 1-B-82

Table 1-B-83

Table 1-B-84

Table 1-B-85

Table 1-B-86

Table 1-B-87

Table 1-B-88

Table 1-B-89

Table 1-B-90

Table 1-B-91

Table 1-B-92

Table 1-B-93

Table 1-B-94

Table 1-B-95

Table 1-B-96

Table 1-B-97

Table 1-B-98

Table 1-B-99

Table 1-B-100

Table 1-B-101

Table 1-B-102

Table 1-B-103

Table 1-B-104

Table 1-B-105

Table 1-B-106

Table 1-B-107

Table 1-B-108

Table 1-B-109

Table 1-B-110

Table 1-B-111

Table 1-B-112

Table 1-B-113

Table 1-B-114

Table 1-B-115

Table 1-B-116

Table 1-B-117

Table 1-B-118

Table 1-B-119

Table 1-B-120

Table 1-B-121

Table 1-B-122

Table 1-B-123

Table 1-B-124

Table 1-B-125

Table 1-B-126

Table 1-B-127

Table 1-B-128

Table 1-B-129

Table 1-B-130

Table 1-B-131

Table 1-B-132

Table 1-B-133

Table 1-B-134

Table 1-B-135

Table 1-B-136

Table 1-B-137

Table 1-B-138

Table 1-B-139

Table 1-B-140

Table 1-B-141

Table 1-B-142

Table 1-B-143

Table 1-B-144

Table 1-B-145

Table 1-B-146

Table 1-B-147

Table 1-B-148

Table 1-B-149

Table 1-B-150

Table 1-B-151

Table 1-C-1

Table 1-C-2

Table 1-C-3

Table 1-C-4

Table 1-C-5

Table 1-C-6

Table 1-C-7

Table 1-C-8

Table 1-C-9

Table 1-C-10

Table 1-C-11

Table 1-C-12

Table 1-C-13

Table 1-C-14

Table 1-C-15

Table 1-C-16

Table 1-C-17

Table 1-C-18

Table 1-C-19

Table 1-C-20

Table 1-C-21

Table 1-C-22

Table 1-C-23

Table 1-C-24

Table 1-C-25

Table 1-C-26

Table 1-C-27

Table 1-C-28

Table 1-C-29

Table 1-C-30

Table 1-C-31

Table 1-C-32

Table 1-C-33

Table 1-C-34

Table 1-C-35

Table 1-C-36

Table 1-C-37

Table 1-C-38

Table 1-C-39

Table 1-C-40

Table 1-C-41

Table 1-C-42

Table 1-C-43

Table 1-C-44

Table 1-C-45

Table 1-C-46

Table 1-C-47

Table 1-C-48

Table 1-C-49

Table 1-C-50

Table 1-C-51

Table 1-C-52

Table 1-C-53

Table 1-C-54

Table 1-C-55

Table 1-C-56

Table 1-C-57

Table 1-C-58

Table 1-C-59

Table 1-C-60

Table 1-C-61

Table 1-C-62

[0086]

[0086] In some embodiments, the compounds provided herein are those of Table 1-A, Table 1-B, or Table 1-C. In some embodiments, the stereoisomers or tautomers of the compounds of Table 1-A, Table 1-B, or Table 1-C are provided herein. In some embodiments, the pharmaceutically acceptable salts of the compounds of Table 1-A, Table 1-B, or Table 1-C are provided herein, or stereoisomers or tautomers thereof.

[0087]

[0087] In one embodiment, the compound provided herein is selected from the group consisting of: (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-1-(4-methylpyrimidine-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-bromo-N-methyl-anilino)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(4-phenylpiperazine-1-yl)sulfonylpropyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-cyclopropyl-2-azabicyclo[2.1.1]hexane-1-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[(2R,5R)-5-phenyltetrahydrofuran-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-hydroxy-1-(3-methylimidazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-oxo-3,4-dihydro-1H-quinoline-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(6,6-difluoro-3-bicyclo[3.1.0]hexanyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-methyl-3-methylsulfonylphenyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-ylmethyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1,2,2-trimethylpyrrolidine-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,2R)-2-hydroxy-4-[(2-phenylimidazol-1-yl)methyl]cyclopentyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(3,6-dihydro-2H-pyridine-1-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[1-(4-fluorophenyl)tetrazol-5-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[4-(2-pyridyl)thiazol-2-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(3aS,6R,6aR)-1-benzyl-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrol-6-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopropylisoxazol-4-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-chlorophenyl)-3-(dimethylamino)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-pyrrolidine-1-ylcyclohexyl)methyl]pyrrolidine-2-carboxamide; 6-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]methyl]-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-8-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[3-(3,3,3-trifluoropropoxy)-4-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-methyl-4-oxophthalazine-1-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(8-chloro-2,3,4,5-tetrahydro-1-benzoxepin-5-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(cyclopropylmethyl)tetrazol-5-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-methyl-5,6,7,8-tetrahydroquinazoline-6-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-chloro-4-fluorophenyl)-3,3,3-trifluoropropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[4-(4-fluorophenyl)thiazol-2-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[(1-phenyltetrazol-5-yl)amino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(2-chlorophenyl)triazol-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[cyclohexyl(3-pyridyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,2S)-2-(1-phenylpyrazole-4-yl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(3-cyclopropyl-3-hydroxy-butyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1R,3S)-2,2-dimethyl-3-phenoxycyclobutyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(6-methyl-1,1-dioxothian-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R,4S)-4-cyano-2-hydroxycyclopentyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[3-(4-cyanophenyl)-1-methylpyrazole-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(2-ethyl-3-oxo-4H-1,4-benzoxazine-7-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-methyl-4-(3-oxopiperazin-1-yl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-isopropyl-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[1-[(2-ethylthiazol-4-yl)methyl]-4-piperidyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[3-(2-fluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine-6-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[5-[(4-fluorophenoxy)methyl]-1,2,4-oxadiazol-3-yl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,2S)-2-(1-naphthyl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-cyclopropyl-1-(3-fluoro-4-methylphenyl)-2-hydroxyethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(2-hydroxy-2-methylpropyl)azetidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1R,2R)-2-(difluoromethyl)cyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(5,5-dimethyl-2-oxopyrrolidine-3-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-hydroxy-2-(4-phenylphenyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[5-(difluoromethyl)isoxazol-3-yl]-1-methylethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(2,4-dimethoxyphenyl)-(4-methoxyphenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[(1-methyl-4-piperidyl)amino]-2-oxo-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[2-fluoro-6-(methanesulfonamide)phenyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[Cyclopropyl(tetrahydropyran-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-methyl-5-phenyl-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3-fluoro-4-methyl-2-pyridyl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-oxabicyclo[4.1.0]heptan-7-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(6-amino-2,4-dimethyl-3-pyridyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[1-[1-(4-bromopyrazole-1-yl)cyclopropyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[1-Cyclopropyl-2-(1,1-Dioxo-1,2-Thiazolidine-2-yl)ethyl]-1-[(2S)-2-(4-Cyclopropyltriazol-1-yl)-3,3-Dimethylbutanoyl]-4-Hydroxypyrrolidine-2-Carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[5-(methoxymethyl)oxazol-4-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1'R,4R)-spiro[chroman-4,2'-cyclopropane]-1'-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[4-(3-chlorophenyl)piperazin-1-yl]-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(4-chloro-2-fluorophenyl)sulfonylamino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[(2-fluorophenyl)methyl]cyclopentyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[2-(2,2-dimethylpropanoylamino)thiazol-4-yl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(2-cyclopentyl-4,5,6,7-tetrahydroindazol-7-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-methyl-2-(4-pyridyl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(2-fluorophenyl)sulfinylethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[5-(difluoromethyl)-2-methylpyrazole-3-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(3-methoxyphenyl)-2-methyl-propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(5-methylpyrimidine-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(tetrazol-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-isoxazol-4-ylpropyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-hydroxy-5,6-dimethylpyridazine-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[3-(5-fluoro-1-methyl-benzimidazol-2-yl)propyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-isopropyl-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-7-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(4,4-dioxo-2,3-dihydro-1,4-lambda6-benzoxatiin-2-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(1,1-dioxothiane-4-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-methyl-6-oxo-3-piperidyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(4-pyridyl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5-methyl-2,3-dihydrobenzofuran-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[3-(1-ethylpropyl)isoxazol-5-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(4-methoxy-1-piperidyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(1-benzyl-2-thiazol-4-ylethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(1-methylimidazol-4-yl)-2-pyrrolidine-1-ylethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(6-methoxy-2-pyridyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-thiazol-2-ylcyclopentyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-[(4-methyl-1-piperidyl)sulfonylmethyl]phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1R,2S)-2-(2,5-dimethoxy-4-methylphenyl)cyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(4-methyl-6-oxopyrimidine-1-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(5-amino-1,3,4-oxadiazol-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[6-(1,1-difluoroethyl)-2-pyridyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-methyl-2-pyrazine-2-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(dimethylamino)-2-(4-ethylphenyl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(4,4-difluoro-1-methyl-3-piperidyl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(2,2-dimethyl-1-pyrimidine-2-yl-propyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(3-hydroxyphenyl)-1-phenyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-hydroxy-1-[2-(trifluoromethoxy)phenyl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(2,2-difluorocyclopropoxy)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-bromotriazolu-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[3-(1,1-dioxo-1,2-thiazolidined-2-yl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-(imidazol-1-ylmethyl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[6-(2-methylmorpholine-4-yl)-3-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(4-methyl-1-piperidyl)-2-phenyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[4-(1,3-benzoxazol-2-yl)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(3-oxomorpholin-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-(4-methoxyphenyl)pyrazole-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[6-(cyclohexoxy)-3-pyridyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(7-oxo-6-azabicyclo[3.2.1]octan-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[2-(m-tolyl)cyclopropyl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[5-oxo-1-(4-phenoxyphenyl)pyrrolidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[4-fluoro-3-[(3-methoxyphenoxy)methyl]phenyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[4-(3-chlorophenoxy)-2-pyridyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[4-(4-ethoxyphenyl)tetrahydropyran-4-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(2-benzylsulfinylethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3,3,3-trifluoro-2-hydroxy-2-(1-methylimidazol-2-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[(1R,2R,4S)-2-hydroxy-4-(4-methyl-1,2,4-triazol-3-yl)cyclopentyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[4-hydroxy-2-[4-(trifluoromethyl)phenyl]butyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[(4-pyrimidine-2-ylpiperazine-1-yl)methyl]cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[[3-chloro-5-(trifluoromethyl)-2-pyridyl]sulfanyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[2-(difluoromethoxy)-4-propoxyphenyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-oxo-2-(thiazol-2-ylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(4-cyclopropyltriazol-1-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-hydroxy-1-methylpyrrolidine-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[5-(1-piperidylsulfonyl)-2-thienyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(3-benzyloxyphenyl)-2-hydroxyethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-[[4-(trifluoromethyl)phenyl]methyl]tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(methylsulfonylmethyl)oxetane-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[2-(1,1-dioxo-1,2-thiazolidined-2-yl)cyclopentyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-phenylisothiazol-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[3-fluoro-1-(2-methylpropanoyl)azetidine-3-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-hydroxy-3-(1-naphthyloxy)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-(4-methylpiperazine-1-yl)pyrimidine-4-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyano-3-pyridyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[phenyl(thiazol-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(1-carbamoyl-1-cyclopropyl-propyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[3-(4-methyl-3-oxopiperazine-1-yl)pyrazine-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(5-phenylthiazol-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-oxo-4H-1,4-benzoxazine-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(2-methylpyrazolo[1,5-a]pyrazine-4-yl)azetidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(2-oxopyrimidine-1-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(5-methyl-1,3,4-oxadiazol-2-yl)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[5-(3-pyridyl)-3-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[6-(benzimidazol-1-yl)-3-pyridyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[6-(4-fluorophenoxy)-2-pyridyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-oxo-1-[4-(trifluoromethyl)phenyl]pyrrolidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,2S)-2-(4-isopropylphenyl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(3-amino-1,2-benzoxazol-6-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(3,4,6,7,8,8a-Hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-ylmethyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(1-carbamoylcyclopropyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(4-cyclopropyl-3-fluorophenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(4-quinolyl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-methylazepan-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(2-methylsulfonylphenyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(2-pyrazole-1-ylphenyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(2,3-dimethylimidazol-4-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-phenylmethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[5-(tert-butoxymethyl)isoxazol-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(2-cyclopropylthiazol-4-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(4,5-dimethyloxazol-2-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-(2,2,2-trifluoroethoxy)cyclohexyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopropyl-1,3,4-oxadiazol-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5-methyl-2-oxo-1-phenyl-pyrrolidine-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R)-2-(6-methoxy-2-naphthyl)-1-methyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(imidazo[1,2-a]pyridine-7-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(4,6-dichloroindan-1-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(8-fluorothiochroman-4-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(tert-butylsulfamoyl)cyclopropyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(2-methyltriazol-4-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-morpholinosulfonylphenyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(4-bromo-3-fluorophenyl)-2-hydroxyethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(5-methyl-1,3,4-thiadiazol-2-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(2-oxo-1-piperidyl)-1-bicyclo[1.1.1]pentanyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(5-oxo-2-phenyl-pyrrolidine-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(2-methylcyclopropyl)-5-oxopyrrolidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[1-(4-fluorophenyl)-1-methyl-ethyl]cyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(4-methylsulfonylphenyl)tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-isobutyl-5-methylpyrazol-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[[2-(trifluoromethyl)benzoyl]amino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2S)-2-(4-bromopyrazole-1-yl)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(6-bromo-1,3-benzoxazol-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(2,6-dichlorophenyl)-1-methyl-ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[2,2-difluoroethyl(ethyl)amino]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(7-methyl-6-oxaspiro[3,4]octan-2-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-isopropoxycyclobutyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(3R,5R)-5-tert-butyl-2-oxo-pyrrolidine-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(2-acetyl-1,3,3a,4,5,6,7,7a-octahydroisoindol-4-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(2-cyclohexylpyrazole-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[5-(1-piperidyl)-1,3,4-oxadiazol-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3-fluorophenyl)-(2-pyridyl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(1,5-diazabicyclo[3.2.2]nonane-6-ylmethyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(3S,4R)-1-benzyl-4-(3-fluorophenyl)pyrrolidine-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[(3,5-dimethoxyphenyl)methyl]pyrrolidine-3-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(6-chloro-8-methylimidazo[1,2-a]pyridine-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[1-[2-(dimethylamino)ethyl]-4-piperidyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(4-oxopyrazolo[1,5-a]pyrazine-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(4-cyclopropyl-2-hydroxy-butyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1-benzyl-2-methylpyrrolidine-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[3-amino-2-[(2-chlorophenyl)methyl]-3-oxopropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-oxo-2-(3-quinolylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(isoxazol-3-ylmethylsulfonylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2R,3R)-2-(trifluoromethyl)chroman-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-2-(1-oxophthalazine-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(3-cyanophenyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1,1-dioxo-2-phenyl-1,2-thiazolidined-5-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(3-cyclopropyl-4,5-dihydroisoxazol-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[(2-phenyloxazol-4-yl)methyl]-4-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[6-[2-(trifluoromethyl)phenoxy]-3-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(2-cyclopropyl-2-hydroxy-2-phenylethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-amino-1-methyl-2-oxo-1-(phenoxymethyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-(3-phenylpropyl)imidazol-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[6-bromo-2-(hydroxymethyl)tetralin-2-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; 2-[4-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]methyl]-1-piperidyl]pyridine-3-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[6-fluoro-2-(4-fluorophenyl)imidazo[1,2-a]pyridine-3-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[1-[(5-tert-butyl-1,2,4-oxadiazol-3-yl)methyl]-3-piperidyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(3-cyano-2-fluorophenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; 3-[1-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-1-methyl-ethyl]-1,2,4-oxadiazol e-5-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[4-(difluoromethyl)-6-methylpyrimidine-2-yl]cyclopentyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(1-cyanocyclohexyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-methyl-2,2-dioxo-3,4-dihydro-2-lambda6,1-benzothiadin-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-methyl-2-phenylthiazol-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[3-(cyclopropylsulfonylamino)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-isopropylisoxazol-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[3-[[2-(2-fluorophenyl)acetyl]amino]phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-chlorophenyl)-3,3,3-trifluoro-2-hydroxypropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[1-(4-cyano-2-fluorophenyl)-3-piperidyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-hydroxy-5,6,7,8-tetrahydroquinoline-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(6-morpholinopyrimidine-4-yl)-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(triazol-1-ylmethyl)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(1-cyanocyclopropyl)methylamino]-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[4-(3-fluorophenyl)-4-hydroxycyclohexyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(1-methyl-5-oxopyrrolidine-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(chroman-6-ylmethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(4-cyclopropyl-2-methylpyrazole-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R)-1-(5-isoquinolyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-methylthiadiazol-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(2,2-dimethyl-3-pyrrolidine-1-yl-propyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-methylcyclopropyl)-phenyl-methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(1-oxo-2-isoquinolyl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[3-(methylcarbamoyl)phenyl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(2,4-difluorophenyl)cyclobutyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(5-isopropyl-2-methyl-1,2,4-triazol-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-amino-4-pyridyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(3,3,4-trimethylpiperazine-1-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(4-methylthiazol-5-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(6-methyl-2-pyrrolidine-1-yl-3-pyridyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-bromophenyl)sulfonyl-2-methylpropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(7-oxoazepan-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-(5-cyanoindan-2-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[(2R,3S)-1-cyclopropyl-5-oxo-2-(4-pyridyl)pyrrolidine-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(oxazol-4-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-2-[4-(2-pyridyl)piperazine-1-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(4-fluoro-1-naphthyl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-methyl-2-pyridyl)-tetrahydropyran-4-yl-methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(3-benzyl-1,2,4-oxadiazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[5-(difluoromethyl)-1-methyltriazol-4-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-[(3-hydroxypyrrolidine-1-yl)methyl]phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(2-fluoro-5-methylphenyl)-2-oxo-3-piperidyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[4-[2-(dimethylamino)ethyl]phenyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(1-cyclohexyl-2-oxo-3-piperidyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-phenylthiazol-2-yl)tetrahydropyran-4-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(5'-bromospiro[cyclopropane-2,1'-indan]-1-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(3-fluoro-2-pyridyl)-2-methylpropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[(4-methoxyphenyl)methylamino]-2-oxo-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[(2-oxo-3,4-dihydro-1H-quinoline-6-yl)oxy]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(6-fluoro-1,1-dioxo-3,4-dihydro-2H-thiochromen-4-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(4-hydroxytetrahydropyran-4-yl)-1-methyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-hydroxy-1-(2-isopropylthiazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(4,5-dimethylthiazol-2-yl)-1-methylethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[7-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(1-methyl-3,6-dihydro-2H-pyridine-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-oxo-2-(5-quinolylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-oxo-2-[1-(2-pyridyl)ethylamino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(3-oxo-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine-2-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R)-1-methyl-2-(1-methyltriazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-cyclopentyl-2-(dimethylsulfamoylamino)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(2,2-dimethyl-1,1-dioxothiolan-3-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(pyridine-2-carbonyl)pyrrolidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[2-bromo-5-(trifluoromethyl)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[3-(dimethylsulfamoyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(1,2-dimethyl-3-piperidyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-methyl-2-(2-methylpyrazol-3-yl)butyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(2,2-difluoronorcalan-7-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[3,5-dimethyl-1-(o-tolyl)pyrazole-4-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-methyl-2-oxo-5,6,7,8-tetrahydroquinoline-5-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[[2-chloro-6-[methyl(3-pyridylmethyl)amino]phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-hydroxy-3-(trifluoromethyl)cyclohexyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-([1,2,4]triazolo[4,3-b]pyridazine-6-yl)pyrrolidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-[(1-benzyl-4-piperidyl)oxy]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-amino-1-(3-bromophenyl)-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,2S)-2-[2-(trifluoromethoxy)phenyl]cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-oxo-2-[4-(1,2,4-triazol-1-yl)anilino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(6R,7R)-2-benzyl-6-hydroxy-3-isopropyl-2-azapiro[3,4]octan-7-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(2-ethylsulfonylphenyl)-4-piperidyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1R,2S)-2-(2,4-difluorophenyl)cyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[(1R,2R)-2-(2,6-difluorophenyl)cyclopropyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[5-(diethylsulfamoyl)-2-thienyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-oxo-3,4-dihydro-1H-1,8-naphthyridine-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[(2S,3R)-2-(1,5-dimethylpyrazole-4-yl)-1-methyl-5-oxopyrrolidine-3-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridine-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,2R,3R,4S)-3-(trifluoromethyl)-7-oxabicyclo[2.2.1]heptan-2-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[3-(2-hydroxyethoxy)-1,1-dioxothiolan-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-[4-(1,2,4-triazol-1-ylmethyl)phenyl]phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[6-(3,4-dihydro-2H-quinoline-1-yl)-3-pyridyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[1-[(3,4-dimethylphenyl)carbamoyl]cyclopentyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-methylimidazo[4,5-b]pyridine-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(5-pyrrolidine-1-yl-2-pyridyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-amino-4-methyl-thiazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-hydroxy-2-(1,3,5-trimethylpyrazole-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-hydroxy-1-(4-methylsulfonylphenyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(cyclopropylsulfonylamino)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(2,4-dimethylphenyl)cyclobutyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[(2S,4R)-1-benzyl-4-methoxypyrrolidine-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(4,6-difluoro-2,3-dihydrobenzofuran-3-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-pyrimidine-2-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(2-ethyl-1,2,4-triazol-3-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(2-chloro-6-fluorophenyl)methyl]-3-hydroxypropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[5-(difluoromethyl)-2-pyridyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(1-methyltetrazol-5-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-methyl-3,4-dihydro-1H-isoquinoline-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-isoxazol-5-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-(2,2,2-trifluoroethyl)pyrazole-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[Cyclopropyl-(4-methylthiazol-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-pyrrol-1-ylpropyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(5-ethyl-2-oxoindoline-3-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(8-cyclopropyl-8-azabicyclo[3.2.1]octan-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; N-(4-bromophenyl)-4-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]piperidine-1-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(2,5-dichlorophenyl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[4-(difluoromethyl)pyrimidine-2-yl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3S,4R)-1-[2-(dimethylamino)pyrimidine-4-yl]-4-methoxypyrrolidine-3-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(2-chloro-6-imidazol-1-ylphenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-phenyl-2-(trifluoromethyl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(1-methylpyrazol-4-yl)sulfonyl-4-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(1,2,4-oxadiazol-3-yl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[5-(dimethylcarbamoyl)tetrahydrofuran-2-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(3,4-difluorophenyl)-2-methylcyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2S,4R)-2-phenylchroman-4-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(1S)-1-(3-bromoisoxazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[2-(dimethylamino)-3-pyridyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[3-(4-acetylpiperazine-1-yl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(2-fluorophenyl)-(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(4-hydroxychroman-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(5-cyano-2-pyridyl)-4-piperidyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[4,4,4-trifluoro-3-hydroxy-3-(5-methyloxazol-2-yl)butyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[3-[(3-fluorophenyl)methylsulfamoyl]phenyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,3S)-3-(cyanomethyl)cyclopentyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[3-(2,3-dihydrobenzofuran-5-yl)-4,5-dihydroisoxazol-5-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[(2S,3R)-1-cyclopropyl-2-(3-methylimidazol-4-yl)-3-piperidyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-amino-3-methyl-benzimidazol-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(1,3-benzodioxo-l-5-yl)cyclopropyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3R)-1-(3-methylisoxazole-5-carbonyl)-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3R)-1-(dimethylsulfamoyl)-3-piperidyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-tetrahydropyran-4-ylcyclopropyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(1-methyltriazol-4-yl)tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-2-(3-methylmorpholine-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-sulfamoylpropyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-cyanophenyl)-1,1-dimethyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-oxazol-5-ylphenyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[(4-fluorophenyl)sulfonylmethylamino]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(4-isopropylphenoxy)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1R,2S)-3,3-difluoro-2-hydroxycyclopentyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(4,4-difluoro-3-morpholino-butyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(1,1-dioxothietan-3-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-pyrrolidine-1-yltetrahydropyran-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(6-isoquinolylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(1,1-dioxo-1,4-thiadinan-4-yl)-1-methyl-2-oxoethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(1,1-dioxothiolan-2-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[5-fluoro-2-(methylsulfonylmethyl)phenyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(6-methoxypyrazine-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(4,4-dioxo-1,4-oxatian-2-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(5-methylimidazo[1,2-a]pyridine-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[3-[(3,5-dimethylpyrazole-1-yl)methyl]phenyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(1,3,4-thiadiazol-2-yl)morpholine-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-cyano-2-methylphenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(5-bromo-2-chlorophenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(2S,3R)-2-(4-fluorophenyl)-1-methylpyrrolidine-3-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(8,8-dioxo-8-lambda6-thiabicyclo[3.2.1]octan-3-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[1-(1,3-benzoxazol-2-yl)-2-phenylethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[1-(1,3-benzothiazol-2-yl)-4-piperidyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(3-cyano-1-phenyl-propyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[5-fluoro-2-(4-hydroxy-1-piperidyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[p-tolyl(1,2,4-triazol-1-yl)methyl]propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-[(1-methyl-4-piperidyl)oxy]phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]cyclobutyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R)-2-benzamidocyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[3-(4-fluoro-3-methylphenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1R,2S)-2-(3-ethoxyphenyl)cyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(5-cyano-2-pyridyl)oxy]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[4-(trifluoromethyl)thiazol-2-yl]propyl]pyrrolidine-2-carboxamide; N-[2-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]ethyl]morpholine-4-carboxamide; (2S,4R)-N-[[3-(1-cyanopropoxy)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[5-(dimethylamino)-1,3,4-oxadiazol-2-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(4-cyano-2-pyridyl)amino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[2-(cyclopentoxy)-3-methoxyphenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(6-carbamoylspiro[3,3]heptan-2-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[1-Carbamoyl-3-(hydroxymethyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(5-ethyl-3-methylisoxazol-4-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(1,1-dioxothiolan-3-yl)oxyethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[1-benzyl-2-oxo-2-(1-piperidyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(2-ethyl-3-oxoisoxazolidine-4-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[5-methyl-1-[3-(trifluoromethyl)phenyl]pyrazole-4-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-[(2-chlorophenyl)sulfonylamino]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(methanesulfonamide)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3R)-1-(4,4,4-trifluorobutanoyl)-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(cyclobutylmethyl)pyrazole-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3,3-dimethyl-5-oxopyrrolidine-2-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-(methanesulfonamide)cyclohexyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(3-bromo-5-methoxyphenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[3-[cyclobutanecarbonyl(cyclopropyl)amino]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(2-phenylpyrazol-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(4-methoxyphenyl)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1,1-dioxo-3,4-dihydro-2H-thiochromen-4-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; 5-Bromo-N-[2-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]ethyl]pyridine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[(3S)-isochroman-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(8-fluoroimidazo[1,2-a]pyridine-2-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[3-(1-methylimidazol-2-yl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[1-ethyl-6-methyl-4-(tetrahydropyran-4-ylamino)pyrazolo[3,4-b]pyridine-5-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[(1-methylimidazol-2-yl)methyl]-2-oxo-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(4-methylsulfonylcyclohexyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[(1S,2R)-1-methylsulfonyl-2-(trifluoromethyl)cyclopropyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[4-(trifluoromethyl)pyrimidine-2-yl]cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(5-methylisoxazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(tetrazol-1-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-morpholinotetrahydropyran-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(1-methylpyrazol-4-yl)-6-oxo-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(4-pyridylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[(1S,3R)-2,2-difluoro-3-methylcyclopropyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[(1R,6R)-7,7-difluoro-2-oxabicyclo[4.1.0]heptan-1-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[4-(2,6-dimethylmorpholine-4-carbonyl)phenyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[4-cyano-4-(2-pyridyl)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[2-(methylcarbamoyl)pyrrolidine-1-yl]-2-oxo-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-[4-[(2-methyl-1-piperidyl)sulfonyl]phenyl]propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-phenyl-1,4-dioxan-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-[isopropyl(methylsulfonyl)amino]propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(1-cyclopropyl-3,3,3-trifluoropropyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-methyl-4,5,6,7-tetrahydroindazol-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(4-pyridyl)azetidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-hydroxy-2-thiazol-5-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,2S)-2-isopropoxy-2-methylcyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-oxo-2-(2,3,4,5-tetrahydro-1-benzazepine-1-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(1-benzhydryl-3-hydroxyazetidine-3-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-(3-methylpyrazol-1-yl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(4-cyclopropyl-5-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-methyl-1-thiazol-2-yl-propyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(p-tolyl)-1-(2-pyridyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3,4-difluorophenyl)-(1-methylimidazol-2-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(3,5-dichlorophenyl)-3-hydroxypropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[3-(4-methylpiperazine-1-carbonyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-5-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(4-benzylmorpholine-2-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1S,3R)-3-(dimethylamino)cyclopentyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1S,3R)-3-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]cyclopentyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-methylimidazo[1,2-b]pyrazole-7-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[(2S)-1-(p-tolyl)pyrrolidine-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(3,4-dichlorophenyl)pyrrolidine-3-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-phenylsulfanylcyclobutyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(4,6-dimethyl-3-pyridyl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-[benzyl(ethyl)amino]-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-acetamidophenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-isopropyl-4-methyl-oxazol-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-bromoindolu-1-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(isobutylsulfamoyl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[1-(difluoromethyl)imidazol-2-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[4-(4-cyanophenyl)tetrahydropyran-4-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(6-methylpyrazine-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S,2R)-2-hydroxy-1,2-diphenyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[benzyl(2-pyridyl)amino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-methylbenzimidazol-2-yl)-phenyl-methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-hydroxy-1-isopropyl-4-piperidyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[3-(3-oxopiperazine-1-yl)sulfonylphenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3,3-bis(hydroxymethyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(2-anilino-1,1-dimethyl-2-oxoethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(1,3-dimethylpyrrolidine-3-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R)-2-(cyclopropylsulfonylamino)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(methylcarbamoyl)cyclohexyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(5-bromo-2-pyridyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-methylsulfonylphenyl)-(p-tolyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[3-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(4-methyl-4-phenyl-cyclohexyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(5-methyl-2-phenyl-oxazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[3-(3-ethyl-1,2,4-oxadiazol-5-yl)cyclopentyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazol-3-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(1-isopropyltriazol-4-yl)-1-methyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[3-(trifluoromethyl)phenoxy]butyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-amino-1-methyl-2-oxo-1-(pyrazol-1-ylmethyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-methylquinuclidin-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(7-bromo-4-oxopyrido[1,2-a]pyrimidine-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-[cyclopropyl(methyl)amino]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[(2,4-dichlorophenyl)methoxy]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[3-(5-cyclopropyl-4-phenyl-1,2,4-triazol-3-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-(5-chloroindolu-1-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(5-bromo-1,3-benzothiazol-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(4-isobutyl-5-methylsulfanyl-1,2,4-triazol-3-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-aminothiazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(4-cyanocyclohexyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(4-hydroxy-6-isopropylpyrimidine-2-yl)pyrrolidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-cyclobutylphenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[5-oxo-1-[[2-(trifluoromethyl)phenyl]methyl]pyrrolidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(5-fluoro-1-methylindol-3-yl)-1-methylethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(1-benzyl-8-oxa-1-azaspiro[4.5]decane-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(2-methoxy-1-naphthyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-imidazol-1-yl-2-methylpropyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[4-(trifluoromethyl)-2-pyridyl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(1-isopropylpyrazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[5-(3-bromophenyl)oxazol-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-methylindan-2-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-tetrahydropyran-2-ylprop-2-inyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-indridine-2-ylethyl)pyrrolidine-2-carboxamide; tert-butyl(4R,5R)-4-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]methyl]-2,2,5-trimethyl-oxazolidine-3-carboxylate; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[4-(dimethylamino)-1-piperidyl]-2-methylpropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(3-oxopiperazine-1-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-2-(1-methyl-4-oxo-pyrazolo[3,4-d]pyrimidine-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[3-(trifluoromethyl)phenyl]cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(6-oxo-7-azapiro[3.5]nonanane-9-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[2-(trifluoromethyl)phenyl]cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(8-oxo-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine-3-yl)methyl]pyrrolidine-2-carboxamide; tert-butyl 2-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]methyl]-4,4-difluoro-2-methylpyrrolidine-1-carboxylate; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,3S)-3-(hydroxymethyl)indan-1-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[(2S,3R)-1-tert-butyl-2-[1-(2-methoxyethyl)pyrazole-4-yl]-5-oxo-pyrrolidine-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[4-(2-methoxyphenyl)piperazine-1-yl]cyclohexyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S,2S,4R,5R)-4-(hydroxymethyl)-2-bicyclo[3.1.0]hexanyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-methyl-6-oxo-4-piperidyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(5-methyl-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-3-yl)methyl]pyrrolinidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-morpholino-2-(2-thienyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[2-chloro-6-(difluoromethoxy)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-ethyl-1-(m-tolyl)cyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[3-(3,5-difluorophenyl)cyclobutyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[3-bromo-2-(difluoromethoxy)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[3-(trifluoromethyl)pyrazole-1-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[5-(4-chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(1-tert-butylpyrazole-4-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5-methyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl)pyrroridine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrrolidine-6-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-methoxy-6-(trifluoromethoxy)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[(1-methylpyrrol-3-yl)sulfonylamino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-pyrimidine-2-yloxypropyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(1-methylcyclobutoxy)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[4-(2-amino-2-oxo-ethyl)tetrahydrofuran-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(2-methoxyethyl)-4,5,6,7-tetrahydroindazol-7-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[[2-(4-fluorophenyl)acetyl]amino]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-methoxy-6-methyl-2-pyridyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[5-(4-fluorophenyl)oxazol-2-yl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(2-ethylsulfinylcyclohexyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-phenyltriazol-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-bromo-2-fluorophenyl)-1-methyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(4-cyclopropyl-1,2,4-triazol-3-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(6-methoxy-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[[3-(trifluoromethyl)-2-pyridyl]amino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[1-(5-fluoro-2-pyridyl)cyclopropyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[1-(3-cyanophenyl)-1-methyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[1-[(4-chlorophenyl)methyl]imidazol-4-yl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[(3-fluorophenyl)methyl]-3-morpholino-3-oxopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[3-(2-cyanoimidazol-1-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(3-cyano-8-oxaspiro[4.5]decane-4-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-(2-propoxyphenoxy)-3-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(2-fluoro-5-methyl-3-pyridyl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(o-tolylmethyl)morpholin-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-hydroxy-2-norbornan-2-yl-propyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-methyl-1,1-dioxothietan-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-[[2-(hydroxymethyl)pyrrolidine-1-yl]methyl]phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[3-(2,6-difluorophenyl)oxetane-3-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[3-[(4-bromophenoxy)methyl]oxetan-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[1-(cyclopentylmethyl)-4-piperidyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[(3S,5R)-4-benzyl-3-(hydroxymethyl)-5-methylmorpholine-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[4-(3-methylisoxazol-5-yl)tetrahydropyran-4-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2,3,4,5-tetrahydrobenzo[i][1]benzoxepin-5-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(2,3-dimethoxy-6,7,8,9-tetrahydro-5H-benzo[7]anulen-5-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[2-(trifluoromethyl)phenyl]cyclopentyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3,3,3-trifluoro-1-(o-tolyl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(4-methoxy-2-naphthyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[2-(difluoromethoxy)phenyl]pyrrolidine-3-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[3-(methylsulfamoyl)anilino]-2-oxo-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(benzenesulfonyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S,3R)-3-(isopropylcarbamoyl)cyclohexyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(methoxymethyl)-2-tetrahydropyran-4-yl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1,1-dioxothiane-3-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(6,7-dihydro-5H-cyclopenta[c]pyridine-4-ylmethyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[5-(dimethylamino)pyrazine-2-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-tetralin-1-yloxypropyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(2-methoxyethyl)-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-tetrahydropyran-4-yl-4-piperidyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(1,2-benzoxazol-3-ylmethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(3-fluoro-4-pyridyl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(3-cyclopropyl-1,2,4-triazol-4-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5-oxopyrrolidine-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(4-aminopyrimidine-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(1-morpholinocyclopentyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(4-oxothieno[3,2-d]pyrimidine-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-pyrimidine-5-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-tetrahydropyran-4-ylsulfonyl-4-piperidyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydrotetrazolo[1,5-a]pyrrolidine-7-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2R,3S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,3R)-3-(4-methylpiperazine-1-yl)indan-1-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(7-methyl-8-oxo-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(3,4-difluorophenyl)-3-methylbutyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[4-(dimethylamino)-2-pyridyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[2-(dimethylamino)-6-methylpyrimidine-4-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(4-isoindorin-2-yl-4-oxobutyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(1-cyclopropyltetrazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(2-methyloxazol-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(4-methyl-2-oxo-3-piperidyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(1-cyclopropyl-2-ethyl-benzimidazol-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]anulen-6-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-chlorophenyl)-2-(cyclopropylmethoxy)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-tetrahydrofuran-2-ylcyclobutyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-[5-(3-bromophenyl)-1,2,4-oxadiazol-3-yl]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(4S)-6,8-dimethylchroman-4-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(isochroman-4-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[4-(5-chloro-2-thienyl)butyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-isopropoxytetrahydrofuran-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3R)-1-(1,3-dimethyl-2,6-dioxopyrimidine-4-yl)pyrrolidine-3-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[1-(5-chloro-2,3-dihydrobenzofuran-7-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(2,2-difluorocyclohexyl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-oxoisoindolin-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(1-ethylbenzimidazol-2-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-([1,2,4]triazolo[1,5-a]pyrimidine-2-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(3-bromo-5-chlorophenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-(4-methoxy-2-pyridyl)cyclohexyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-(1,2,4-triazol-1-yl)cyclopropyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-spiro[2-oxabicyclo[3.2.0]heptane-7,1'-cyclobutane]-6-ylpyrrolidine-2-carboxamide; (2S,4R)-N-[2-[cyclohexyl(ethyl)sulfamoyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-methyl-1,1-dioxothian-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-[1-(4-chlorophenyl)cyclobutyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(2-fluoro-3-methoxyphenyl)cyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,2S,4R,5R)-5-methoxy-5-(trifluoromethyl)norbornan-2-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-2-yl)cyclopentyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[(2,4-dimethoxyphenyl)methyl]-2-oxopyrrolidine-3-yl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[4-hydroxy-3-(4-methylpiperazine-1-yl)butyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(E)-3-(3-pyridyl)allyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(1-cyclopropyl-5-methyl-pyrrolidine-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[5-(1-hydroxyethyl)-6-methyl-2-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[3-(dimethylamino)-4-methylpentyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1,1-dimethyl-3-(4-methylpiperazine-1-yl)propyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-(benzylsulfamoyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(4-fluorophenyl)-(1-methylpyrazole-4-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[3-(2-methoxyphenyl)isoxazol-5-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(5-methyltetrazol-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(phenoxymethyl)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-hydroxy-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3R,4R)-4-hydroxy-1-isopropyl-pyrrolidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-5-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(hydroxymethyl)-3,6,7,8,9,9a-hexahydro-1H-pyrido[2,1-c][1,4]oxazin-4-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-(hydroxymethyl)cyclohexyl]-phenyl-methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(5-bromo-2-methoxyphenyl)-2-hydroxyethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; N-[4-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]methyl]phenyl]-N-methylpyridine-4-carboxamide; (2S,4R)-N-[1-Cyclopropyl-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-2-(5-methyl-2-phenylpyrazole-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-([1,2,4]triazolo[4,3-a]pyrazine-8-yl)-3-piperidyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(5-oxo-1,4-dihydro-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(4-methylphthalazine-1-yl)-4-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3,3-dimethyltetrahydropyran-2-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-oxo-3-(4-pyrazine-2-ylpiperazine-1-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2R,3S)-1-methyl-5-oxo-2-(1,3,5-trimethylpyrazole-4-yl)pyrrolidine-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-isochroman-7-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1,1-dioxo-4H-1-lambda6,2,4-benzothiadiazine-3-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[4-(3-ethyl-1,2,4-oxadiazol-5-yl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R)-6-bromo-1-hydroxytetralin-2-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-1-(1-methylpyrazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(2-oxo-1-pyridyl)-1-phenyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[4-(difluoromethoxy)cyclohexyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(trifluoromethyl)-3-thienyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(3-bromoimidazo[1,2-a]pyridine-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(2-benzyl-3-oxoisoindolin-1-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-imidazo[1,2-a]pyrimidine-2-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[1-[3-fluoro-5-(trifluoromethyl)phenyl]cyclopropyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(1S,2R)-2-tert-butoxy-1-(methylcarbamoyl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[3-fluoro-4-(2-methylimidazol-1-yl)phenyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[1-(3-fluorophenyl)pyrazole-3-yl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[[6-(trifluoromethyl)-2-pyridyl]oxy]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[3-(2,5-dimethylpyrazole-3-yl)oxypropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(1,2,4-triazol-1-yl)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(2,3-difluorophenyl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopropyloxazol-4-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1R)-1-(5-fluoro-3-pyridyl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(4-tert-butyl-3-pyridyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(7-chlorochroman-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-oxo-1,3-dihydroimidazol-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[1-(difluoromethylsulfonyl)-4-piperidyl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-isopropyl-4,5,6,7-tetrahydroindazol-6-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(3-methylimidazol-4-yl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(2-quinolylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(1,3-dimethylpyrazole-4-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-methyl-2-(2-thienyl)-3-piperidyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-2-(2-methylindoline-1-yl)-2-oxoethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(6,6-difluoro-2-bicyclo[3.1.0]hexanyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-hydroxy-5-methoxyindan-1-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3,3,3-trifluoro-2-pyrazole-1-yl-propyl)pyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[[2-methoxyethyl(methyl)amino]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; Ethyl 1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-4-carboxylate; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(2-hydroxy-3,3-dimethyl-butyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methylthiazol-4-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-chloro-2-thienyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(4-methyl-1-piperidyl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(methanesulfonamidemethyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(1,4-dioxa-9-azaspiro[4.5]decane-9-yl)ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3,4-difluorophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(2,2,6,6-tetramethylmorpholine-4-yl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; Methyl 1-[[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methyl]piperidine-2-carboxylate; (2S,4R)-1-[(2S)-2-[4-[2-(3,3-dimethyl-1-piperidyl)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4,4-dimethyl-1-piperidyl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-phenylpiperazine-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-methylsulfanylphenyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[(tetrahydrofuran-3-ylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[tert-butyl(methyl)amino]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-methyl-1-piperidyl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(4-methylsulfonylpiperazine-1-yl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-methylpiperazine-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(azepan-1-ylmethyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(diisopropylamino)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[(1-methyl-2-piperidyl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-oxopiperazine-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(4-methoxy-1-piperidyl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1-methylpyrrolidine-2-yl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(4,4-dimethyl-1-piperidyl)ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(2S,6R)-2,6-dimethylmorpholine-4-yl]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[3-(3,3-dimethyl-1-piperidyl)propyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(2-fluorophenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(3,3-dimethylazepan-1-yl)ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[[2-(hydroxymethyl)pyrrolidine-1-yl]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1-methyl-2-piperidyl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(2,2-dimethylmorpholine-4-yl)ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2,6-difluorophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(1,1-dioxo-1,4-thiazepan-4-yl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-methoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(5-methoxy-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(6-methoxy-2-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(2-chlorophenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3-chlorophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-methylphenoxy)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-[2-(4-fluorophenyl)-1-(methylamino)ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; 1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methyl]piperidine-4-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-cyano-1-piperidyl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4,4-difluoro-1-piperidyl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(1-methyl-4-piperidyl)amino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(4-methylsulfanylphenyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-hydroxy-3,3-dimethyl-butyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2,6-dimethyl-4-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-(1-benzylpyrrolidine-3-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(1-isopropylpyrazole-4-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-chloro-2-fluorophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-acetylpiperazine-1-yl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; 3-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methylamino]benzoic acid; (2S,4R)-1-[(2S)-2-[4-(3,5-dichlorophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; Methyl 4-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]benzoate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-oxo-3-(p-tolyl)propyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; Methyl 4-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]-2-methylpyrazole-3-carboxylate; Methyl 6-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]pyridine-2-carboxylate; Methyl 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methyl]benzoate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(2,2,2-trifluoroacetyl)amino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(ethylsulfonylamino)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[(3-methyl-1,1-dioxo-1,4-thiadinan-4-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(tetrahydropyran-4-ylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[2-(morpholinomethyl)imidazol-1-yl]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; tert-butyl 4-[1-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]-1-methylethyl]piperazine-1-carboxylate; (2S,4R)-1-[(2S)-2-[4-(2-chlorophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methylsulfonylethyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[1-(tert-butylamino)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; tert-butyl 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperazine-1-carboxylate; (2S,4R)-1-[(2S)-2-[4-(4-amino-3-chlorophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(4-methylpiperazine-1-yl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[Cyclohexyl(methyl)amino]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(6-aminopurine-9-yl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(6-azaspiro[3.5]nonane-6-yl)ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1-piperidyl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-benzoyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-chloropyrazol-1-yl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(isoindoline-2-ylmethyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[1-(methanesulfonamide)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-methoxybenzoyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3-acetylphenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-acetylphenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; Methyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]pyridine-2-carboxylate; Methyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2,2-dimethyl-propanoate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1,2,4-triazol-1-yl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-oxo-1-piperidyl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(6-fluoro-5-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(5-hydroxy-3-oxopentyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-oxospiro[3,3]heptan-6-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-cyano-3-fluorophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(6-fluoro-4-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(2-methoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-oxoazepan-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(6-fluoro-2-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-oxomorpholin-4-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(2-methoxy-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(1-hydroxycyclohexyl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[6-(hydroxymethyl)-2-pyridyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[3-(hydroxymethyl)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-cyanophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-fluoro-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-cyclopropylthiazol-2-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(2,5-dimethylpyrrol-1-yl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(2-methoxythiazol-5-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(6-methoxy-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-sulfamoylpropyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(dimethylcarbamoylamino)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[methyl(methylsulfonyl)amino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-chloro-2-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(cyclopropylsulfonylamino)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3,5-dimethylpyrazole-1-yl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-methoxy-2-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(1-methylpyrazole-4-yl)oxymethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methyl-1-pyrrol-1-ylethyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2-fluoro-5-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-propylpyrazole-4-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[4-(hydroxymethyl)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-oxo-3-phenyl-propyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-chloro-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[[1-(hydroxymethyl)cyclobutyl]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(methylamino)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[2-(methanesulfonamide)ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(dimethylsulfamoyl)ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2,6-dichlorophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4,4-dimethyl-3-oxopentyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]benzoic acid; Methyl 4-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]cyclohexanecarboxylate; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-hydroxytetrahydropyran-4-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; Methyl 6-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]pyridine-3-carboxylate; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[hydroxy(phenyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(pyrimidine-2-yloxymethyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-[(4-tert-butylphenyl)-hydroxymethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2-ethoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4,4-difluorocyclohexyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-(2-tetrahydropyran-2-ylethyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3-bromo-4-methoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2-fluoro-4-methoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-(1,1-dioxothiane-3-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(1-hydroxy-1-phenyl-ethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(N-methylanilino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(benzyloxymethyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(p-tolylsulfonylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(2-cyanophenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-[4-(4-fluorophenyl)-3-hydroxy-butyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3-chlorophenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(2-thienylmethylamino)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(2-amino-2-oxo-ethyl)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-[(4-chlorophenyl)-hydroxymethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(3-cyanophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[4-(trifluoromethyl)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(6-ethoxy-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-quinolyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(3-methoxy-2-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; Benzyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]-2,2-dimethylpropanoate; Ethyl 5-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]-1-methylpyrazole-4-carboxylate; Ethyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]benzoate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1,3,5-trimethylpyrazole-4-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; Ethyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2,2-dimethyl-propanoate; Ethyl 2-[[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]tetrahydrofuran-2-carboxylate; [1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]cyclohexyl]carbamate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(thiazol-2-ylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-oxo-1-pyridyl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5,8-dioxaspiro[3,4]octan-2-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(benzamidomethyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(3,4-difluorophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-(4-indan-5-yltriazol-1-yl)-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[2-hydroxy-2-(2-thienyl)propyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(4-methoxyanilino)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(benzenesulfonamidemethyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[3-[(2-fluoro-3-pyridyl)oxy]propyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[1-[4-(hydroxymethyl)phenoxy]propyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-phenylimidazol-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[1-(cyclopropanecarbonylamino)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-[2-(2-cyanoethyl)-1,3-dioxolan-2-yl]ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[3-(methoxymethyl)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(2-fluorophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methyl-4,5,6,7-tetrahydroindazol-3-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methylbenzimidazol-2-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-chloro-2-methoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[6-(trifluoromethyl)-3-pyridyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-phenoxyethyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[4-(trifluoromethyl)anilino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[[3-(hydroxymethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[[4-(hydroxymethyl)cyclohexoxy]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(p-tolylcarbamoylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[5-[(2-methoxypyrimidine-4-yl)-methyl-amino]-2-methyl-phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4,4-dioxo-4-lambda6-thia-5-azapiro[2.5]octan-5-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[[4-(hydroxymethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-(4-imidazo[1,2-a]pyridine-2-yltriazol-1-yl)-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(difluoromethoxy)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-cyclopropyloxazol-4-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[5-(trifluoromethoxy)-2-pyridyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(4-pyridylmethylamino)phenyl]triazol-1-yl]butanoyl]4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-[(4-fluorophenyl)-hydroxymethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; tert-butyl 2-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]pyrrolidine-1-carboxylate; (2S,4R)-1-[(2S)-2-[4-(2-chloro-4-methoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(1,3-benzothiazol-2-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-quinolyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(2-chlorophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(2-methoxyphenyl)sulfanylmethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(2-hydroxy-2-phenylethyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(1-hydroxy-2-phenylethyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[3-hydroxy-3-(2-pyridyl)propyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-methylbenzimidazol-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; N-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methyl]pyridine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-tert-butoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; N-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]-6-oxo-1H-pyridine-3-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[hydroxy(p-tolyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-phenylphenyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(3-nitrophenyl)carbamoylamino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-phenylimidazol-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(5,6-dimethylbenzimidazol-1-yl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(phenylcarbamoylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4,4-difluoro-1-hydroxycyclohexyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(1,1-dioxo-1,4-thiadinan-4-yl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-methyl-5-(trifluoromethyl)pyrazole-3-yl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[6-(trifluoromethyl)-2-pyridyl]oxymethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(5-aminopyrazine-2-yl)-methyl-amino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[[4-(hydroxymethyl)phenyl]sulfanylmethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; N-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methyl]-2-methylpyrazole-3-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(5-oxo-1,4-oxazepan-4-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(3-hydroxy-3-phenyl-propyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[4-methyl-3-(phenylcarbamoyl)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-phenylindol-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-phenylphenyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-ethoxy-2,3-difluorophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[3-[(4-cyanophenyl)sulfonylamino]phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-methylsulfonylphenoxy)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(2-methoxyphenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(ethylamino)-4-pyridyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[1-(cyclopropylsulfonylamino)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(5-isoquinolyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[methyl(p-tolylsulfonyl)amino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[4-hydroxy-4-(2-pyridyl)butyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(1-hydroxy-4,4-dimethylcyclohexyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; tert-butyl 7-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-4-azaspiro[2,4]heptane-4-carboxylate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-sulfamoylcyclobutyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[hydroxy-[3-(trifluoromethyl)phenyl]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; N-benzyl-1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol e-4-carboxamide; (2S,4R)-1-[(2S)-2-[4-[4-(dimethylamino)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(2-methoxy-1-naphthyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3,5-difluorophenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-chlorophenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[3-(benzylamino)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methylsulfonyl-4-piperidyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[1-(dimethylsulfamoyl)cyclopropyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[[3-(1-hydroxyethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; 5-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]pyridine-3-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[6-(trifluoromethyl)-2-pyridyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[4-(2,2,2-trifluoro-1-hydroxy-ethyl)phenyl]triazol-1-yl]butanoyl]4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3-fluoroanilino)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[(5-hydroxy-2-oxo-1-piperidyl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-acetamidophenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(trifluoromethyl)benzoyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3,5-dimethyl-1,2,4-triazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; tert-butyl 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]-1,4-diazepane-1-carboxylate; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(2-hydroxynorbornan-2-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[[4-(1-hydroxyethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(4-isopropylcyclohexyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[[4-(1-hydroxypropyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(5-phenyl-2-thienyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-isoquinolyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; tert-butyl 1-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2-azabicyclo[2.1.1]hexane-2-carboxylate; (2S,4R)-1-[(2S)-2-[4-[4-(cyclobutoxy)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(1-cyanocyclohexyl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(2-isopropoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[1-(4-fluorophenyl)cyclopropyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; tert-butyl 2-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]morpholine-4-carboxylate; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(1-hydroxy-1-methyl-2-phenyl-ethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(indol-1-ylmethyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; tert-butyl 3-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]azetidine-1-carboxylate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(trifluoromethyl)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-isopropoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(3-cyanobenzoyl)amino]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(6-isopropoxy-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(3-hydroxyphenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-phenylcyclopropyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3,4-dimethoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3,4,5-trimethylpyrazole-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[2-(3-hydroxy-3-methyl-1-piperidyl)ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; tert-butyl 7-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]indoline-1-carboxylate; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(6-isoquinolyl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2-chloro-5-methoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-(4-tetralin-5-yltriazol-1-yl)butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[5-(trifluoromethyl)-2-pyridyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[3-(isopropylamino)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(3-methoxyphenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-methylphenoxy)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(5-cyanopyrazine-2-yl)-methyl-amino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[4-(cyclopentoxy)phenyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(2-hydroxy-3-phenyl-propyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-fluorophenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(5-quinolyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-ethoxy-3-fluorophenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-(4-quinoxaline-2-yltriazol-1-yl)butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-tert-butylphenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3-cyanophenoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-(4-isopropenyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methyl-4-piperidyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-[4-[amino(tetrahydrofuran-2-yl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-cyano-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(6-cyano-3-pyridyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(2-ethylimidazol-1-yl)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5-methyltetrahydrofuran-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(3-methoxyisothiazol-5-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-[tert-butyl(methyl)amino]ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3,3-dimethoxycyclobutyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(1H-indol-5-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-sulfamoylcyclopropyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; 4-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]benzoic acid; 6-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]pyridine-3-carboxylic acid; 5-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]pyridine-3-carboxylic acid; (2R,4S)-4-hydroxy-1-[(2R)-2-[4-[2-hydroxy-2-(2-pyridyl)ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-oxazol-5-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-fluoroanilino)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(6-quinolyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-aminocyclohexoxy)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; 3-Hydroxy-3-[[1-[(1S)-1-[(2S,4R)-4-Hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methyl]cyclobutancarboxylic acid; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-oxothiolan-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-chloro-1,3-dimethylpyrazole-4-yl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3-cyclobutylphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(1-oxo-1,4-thiadinan-4-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-N-(2-cyanocyclohexyl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3-hydroxypyrazine-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[3-(1-hydroxy-1-methyl-ethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[4-(aminomethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5-methyl-5-azapiro[2,4]heptan-7-yl)pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,5S,6S,7R)-7-hydroxy-6-bicyclo[3.2.0]heptanyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3,5-dimethyl-4H-isoxazol-5-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-methyl-5-oxo-pyrrolidine-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-chloroanilino)methyl]triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[(3R,4S)-4-hydroxytetrahydrofuran-3-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-chloro-3-methoxyphenyl)triazol-1-yl]-3,3-dimethylbutanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methyl-6-quinolyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(trifluoromethyl)-2-pyridyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-7-yl)pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(2-hydroxy-4-pyridyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,2R)-2-(2-methylpyrazole-3-yl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrrolidine-8-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(1-benzyloxy-1-methyl-ethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5-oxo-6-azapiro[3,4]octan-2-yl)pyrrolidine-2-carboxamide; (2R,4S)-N-(1-cyclopropyl-4-methyl-pyrrolidine-3-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-methyl-2-azabicyclo[2.2.2]octan-6-yl)pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-4-yl)pyrrolidine-2-carboxamide; 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methoxy]benzoic acid; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(5-oxo-1,2-dihydropyrazole-3-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5-methyl-6-oxabicyclo[3.2.1]octan-1-yl)pyrrolidine-2-carboxamide; 2-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methoxy]pyridine-3-carboxylic acid; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-nitrophenoxy)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(hydroxymethyl)norbornan-2-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-hydroxy-3-(triazol-1-yl)propyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[3-(dimethylamino)-2,2-dimethylcyclobutyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(5-methylisoxazol-3-yl)carbamoylamino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[(2S,4R)-4-methoxytetrahydropyran-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-methylsulfonylphenyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; Methyl 1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methyl]piperidine-4-carboxylate; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-([1,2,4]triazolo[4,3-a]pyridine-6-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydroisoquinoline-5-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1,1-dioxo-1,2-thiazolidined-3-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,2S)-2-(1,2,4-triazol-4-yl)cyclopentyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-methyl-4,5,6,7-tetrahydrobenzotriazol-5-yl)pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-methyl-4,5,6,7-tetrahydroindazol-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopropyl-2-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrrolidine-8-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-hydroxy-2-pyrazole-1-yl-cyclobutyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-[[2-(methylamino)-2-oxoethyl]amino]phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(2-ethylimidazol-1-yl)-1-methylethyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-methyl-3-(2-methylimidazol-1-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(2S,3R)-2-cyclopropyl-6-oxo-3-piperidyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,5R,6R)-3-carbamoyl-6-bicyclo[3.2.0]heptanyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(5-methoxy-1,3-dimethylpyrazole-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-tert-butyltetrazol-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(1,1-dimethyl-2-oxo-2-pyrrolidine-1-ylethyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-isoquinolylmethyl)pyrrolidine-2-carboxamide; Ethyl 3,3,3-trifluoro-2-hydroxy-2-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]propanoate; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(2,2-difluorospiro[2,4]heptan-1-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-methylsulfinylcyclohexyl)pyrrolidine-2-carboxamide; (2R,4S)-4-hydroxy-1-[(2R)-2-[4[2-[3-(hydroxymethyl)-3-methoxy-1-piperidyl]ethyl]triazol-1-yl]-3,3-dimethylbutanoyl]-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydroquinoline-8-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[Cyclobutyl(2-pyridyl)methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[2-(cyclopropylamino)-4-pyridyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-cyclopropylpyrimidine-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(3-pyrimidine-2-yltetrahydrofuran-3-yl)pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(4-methoxy-1,1-dioxothiolan-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(3-fluoro-2-pyridyl)cyclobutyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(hydroxymethyl)-3-(4-pyridyl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclobutyl-4-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopentylisoxazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-isopropoxypyrimidine-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(5-tert-butylisoxazol-3-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-N-[1-(3-tert-butyl-1,2,4-oxadiazol-5-yl)ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(4-chloro-2,3-dihydrobenzofuran-3-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(2-oxopyrrolidine-1-yl)pentyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(2,2-diethyl-3-methoxy-4-methylcyclobutyl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-phenyl-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-hydroxy-2-quinolyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(3,5-dimethoxyisothiazol-4-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(1-cyclopropyl-1-methyl-2-phenyl-ethyl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1-methyl-3,4-dihydro-2H-quinoline-3-yl)methyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(2,3-dimethyl-1,1-dioxo-1,2-thiazolidined-3-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide; 5-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]methyl]-N,N-dimethylpyridine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-oxo-3-(3-pyridylmethylamino)propyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(4-chloro-1,1a,6,6a-tetrahydrocyclopropa[a]inden-1-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(1-methylimidazol-2-yl)-4-piperidyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-isopropyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrrolidine-6-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1R,2S)-2-(4-fluoro-3-methoxyphenyl)cyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-N-[1-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-2-methylpropyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-N-[1-(1-tert-butyl-3-methylpyrazole-4-yl)ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(1-tetrahydrofuran-3-yltriazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[5-(trifluoromethyl)tetrahydrofuran-2-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[Cyclopropyl-(2,4-difluorophenyl)methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1R)-5,7-difluorotetralin-1-yl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-N-(3-tert-butoxyspiro[3.3]heptan-1-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[2-(difluoromethoxy)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[3,3-difluoro-1-(imidazol-1-ylmethyl)cyclobutyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(1-phenylimidazol-2-yl)ethyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(1,5-dimethylindol-3-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(1-methyl-2-oxoindoline-5-yl)ethyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-methyl-1-([1,2,4]triazolo[4,3-a]pyridine-3-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1R,2S)-2-(2,3-dihydro-1,4-benzodioxin-5-yl)cyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-(1,1-dioxo-7-oxa-1-lambda6-thiaspiro[3.5]nonanane-3-yl)-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2S,3R)-2-(p-tolyl)tetrahydropyran-3-yl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(5-isopropoxyindan-1-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-(2-pyridylmethyl)pyrrolidine-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(6-aminopurine-9-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(methanesulfonamidemethyl)cyclopentyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(4-fluoro-1-methyl-benzimidazol-2-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-[(4-fluorophenyl)carbamoyl]cyclopropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2S,3R)-2-(1-methylpyrazol-4-yl)-6-oxo-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(3R,4R)-3-(pyrimidine-4-ylamino)tetrahydropyran-4-yl]pyrrolidine-2-carboxamide; (2R,4S)-N-[3-amino-1-(6-methoxy-3-pyridyl)-3-oxopropyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(4-fluorophenyl)-tetrahydrofuran-2-yl-methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1R,3R)-3-morpholinospiro[3,3]heptan-1-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-(2-hydroxycyclohexyl)-4-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(1S)-1-(cyclohexylcarbamoyl)-2-methylpropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(2-morpholinothiazol-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-(2-pyridyl)spiro[3,3]heptan-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-(2-isopropyl-1,3-benzoxazol-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-spiro[chroman-2,3'-tetrahydrofuran]-4-ylpyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[1-(4-pyridyl)ethyl]-4-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(4-methyl-2-morpholinophenyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-(methanesulfonamide)cyclohexyl]methyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[1-(methoxymethyl)isochroman-1-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(1S)-1-[3-[2-(dimethylamino)ethoxy]phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-[(2-morpholino-2-oxo-ethyl)amino]phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[(2R,3S)-2-(1-ethylpyrazole-4-yl)tetrahydropyran-3-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-(2,5-dimethoxyphenyl)-2-hydroxy-1-methyl-ethyl]-4-hydroxypyrrolidine-2-carboxamide; tert-butyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-2-(p-tolylsulfonyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[3-[methyl(methylsulfonyl)amino]phenyl]methyl]pyrrolidine-2-carboxamide; (2R,4S)-N-[1-(1-benzylimidazol-2-yl)propyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(2,4-dimethylphenyl)-2-imidazol-1-ylethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-pyrrolidine-1-yltetralin-1-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[[6-(difluoromethoxy)-1,3-benzodioxo-1-5-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(7-benzyloxy-6-bicyclo[3.2.0]heptanyl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-cyclopentylsulfanylpyrimidine-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-(5-chloro-1-oxo-3,4-dihydroisoquinoline-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-chloro-6-pyrrolidine-1-ylphenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(8-phenylchroman-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[4-(cyclopentanecarbonyl)piperazine-1-yl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-indoline-1-ylsulfonylethyl)pyrrolidine-2-carboxamide; (2R,4S)-N-[1-[(2-aminothiazol-5-yl)methyl]-3-methyl-4-piperidyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[2-[(3-fluoro-4-methylphenyl)sulfamoyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(2R,3S)-1-cyclopropyl-2-(3-methoxyphenyl)pyrrolidine-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(3,4-dihydro-1H-isoquinoline-2-ylmethyl)-2,2-dimethylpropyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[3-(4-chlorophenyl)sulfonylpropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[1-[(3-chlorophenyl)methyl]-2-piperidyl]methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-N-[1-[4-(4-chloropyrazole-1-yl)-3-fluorophenyl]ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-(3-bromo-6,7,8,9-tetrahydro-5H-benzo[7]anulen-6-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-N-[(4-chlorophenyl)-(4-methylmorpholine-2-yl)methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[(2,5-dichlorophenyl)-tetrahydrofuran-3-yl-methyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[[4-tert-butoxy-2-(trifluoromethyl)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-methyl-3-[4-(m-tolyl)piperazine-1-yl]propyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-[methyl-(1-methyl-4-piperidyl)amino]-1-phenyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(4-bromophenyl)pyrazole-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-N-[1-[8-chloro-6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-3-yl]ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-N-[1-(3,4-dichlorophenyl)-2-(2-pyridyl)ethyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[(2R,3S)-2-(4-chloro-3-fluorophenyl)-1-isopropyl-5-oxopyrrolidine-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(3-bromo-1-methyl-pyrazolo[3,4-d]pyrimidine-4-yl)amino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[4-[(2-methyltetrazol-5-yl)sulfamoyl]phenyl]ethyl]pyrrolidine-2-carboxamide; Methyl 1-[[1-[(1R)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]methyl]piperidine-2-carboxylate; (2R,4S)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[3-(3-pyridyl)aryl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(2-methyl-5-tetrahydrofuran-2-ylpyrazole-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(7-hydroxypyrazolo[1,5-a]pyrimidine-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[5-(methanesulfonamide)-2-methoxyphenyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-(1-methyl-4-phenyl-4-piperidyl)pyrrolidine-2-carboxamide; and (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-[1-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidyl]pyrrolidine-2-carboxamide, or its stereoisomers or tautomers, or any of the aforementioned pharmaceutically acceptable salts.

[0088]

[0088] In some embodiments, the compounds provided herein are those of Table 2. In some embodiments, the stereoisomers or tautomers of the compounds of Table 2 are provided herein. In some embodiments, the pharmaceutically acceptable salts of the compounds of Table 2 are provided herein, or their stereoisomers or tautomers. Table 2 [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5]

[0089]

[0089] In some embodiments, the compounds provided herein are those of Table 2A. In some embodiments, the stereoisomers or tautomers of the compounds of Table 2A are provided herein. In some embodiments, the pharmaceutically acceptable salts of the compounds of Table 2A are provided herein, or their stereoisomers or tautomers. Table 2A [Table 2A]

[0090]

[0090] The compounds described herein may exist in solid or liquid form. In the solid state, the compounds may exist in crystalline or amorphous form, or as mixtures thereof. Those skilled in the art will understand that pharmaceutically acceptable solvates may be formed for crystalline or amorphous compounds. In crystalline solvates, solvent molecules are incorporated into the crystal lattice during crystallization. Solvates may contain, but are not limited to, non-aqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, or ethyl acetate, or they may contain water as the solvent incorporated into the crystal lattice. Solvates in which water is the solvent incorporated into the crystal lattice are generally called “hydrates.” Hydrates include stoichiometric hydrates, as well as compositions containing varying amounts of water. The subject matter described herein includes such solvates.

[0091]

[0091] Those skilled in the art will further understand that certain compounds described herein, including their various solvates, which exist in crystalline form, may exhibit polymorphism (i.e., the ability to occur in different crystalline structures). These different crystalline forms are typically known as “polymorphs.” The subject matter disclosed herein includes such polymorphs. Polymorphs have the same chemical composition but differ in packing, geometric arrangement, and other descriptive properties of the crystalline solid state. Thus, polymorphs may have different physical properties such as shape, density, hardness, deformability, stability, and solubility. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which can be used for identification. Those skilled in the art will understand, for example, that different polymorphs can be produced by changing or adjusting the reaction conditions or reagents used in the production of the compound. For example, changes in temperature, pressure, or solvent can result in polymorphism. Furthermore, one polymorph may spontaneously transform into another under certain conditions.

[0092]

[0092] The compounds described herein or their pharmaceutically acceptable salts may exist as stereoisomers (for example, containing one or more chiral carbon atoms). Each stereoisomer (enantiomer and diastereomer) and mixtures thereof are included in the scope of the subject matter disclosed herein. Similarly, the compounds or salts described herein may exist in tautomers other than those shown in their formulas, and these are also understood to be included in the scope of the subject matter disclosed herein. The scope of the subject matter disclosed herein includes, in addition to mixtures of stereoisomers, purified enantiomers or enantiomerically / diastereomerically concentrated mixtures.

[0093]

[0093] The subject matter disclosed herein also includes isotopically labeled forms of the compounds described herein, except that one or more atoms are replaced by atoms having atomic masses or mass numbers different from those normally found in nature. Examples of isotopes that can be incorporated into the compounds described herein and their pharmaceutically acceptable salts include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, for example, 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I is included.

[0094]

[0094] Compounds disclosed herein and pharmaceutically acceptable salts thereof containing the above-mentioned isotopes and / or other isotopes of other atoms are within the scope of the subject matter disclosed herein. Isotope-labeled compounds, for example 3 H, 14 This specification discloses products incorporating radioactive isotopes such as 13C, which are useful in drug and / or substrate tissue distribution assays. Tritium-labeled (i.e., 3 H) and carbon-14 (i.e., 14 C) Isotopes are commonly used to facilitate their preparation and for their detectability. 11 C and 18 The fluorine isotope is useful in PET (positron emission tomography), 125 I isotopes are useful in SPECT (single-photon emission computed tomography), and all are useful in brain imaging. Furthermore, deuterium (i.e., 2Substitution with heavier isotopes, such as H), can offer certain therapeutic benefits resulting from improved metabolic stability (e.g., extended half-life in vivo or reduced drug-related requirements) and is therefore preferred in some situations. Isotope-labeled compounds can generally be prepared by performing the disclosed procedures, using readily available isotope-labeled reagents in place of non-isotope-labeled reagents.

[0095] III.C. formulations

[0095] In additional embodiments, the Specified herein provides therapeutic or pharmaceutical compositions comprising an effective amount of at least one of the compounds described herein. Pharmaceutical compositions comprising an effective amount of at least one of the compounds of the Disclosure, in combination with a pharmaceutically effective amount of a carrier, excipient, or additive and optionally an additional bioactive agent, represent further embodiments of the Disclosure.

[0096]

[0096] In certain embodiments, the composition comprises a pharmaceutically acceptable salt, in particular an acid- or base-added salt of the compounds described herein. Acids used to prepare the pharmaceutically acceptable acid-added salts of the base compounds described above include those that form non-toxic acid-added salts, i.e., salts containing pharmaceutically acceptable anions, such as hydrochlorides, hydrobroms, hydroiodides, nitrates, sulfates, bisulfates, phosphates, acidic phosphates, acetates, lactates, citrates, acidic citrates, tartrates, hydrogen tartrates, succinates, maleates, fumarates, glucons, sugarates, benzoates, methanesulfons, ethanesulfons, benzenesulfons, p-toluenesulfons, and pamoates [i.e., 1,1'-methylene-bis-(2-hydroxy-3 naphthonate)].

[0097]

[0097] Pharmaceutically acceptable base addition salts can also be used to prepare pharmaceutically acceptable salt forms of the compounds or derivatives. Chemical salts that can be used as reagents for preparing pharmaceutically acceptable base salts of the compounds of the present invention, which are essentially acidic, are those that form non-toxic base salts of such compounds. Such non-toxic base salts include, but are not limited to, those derived from pharmaceutically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium, zinc, and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.

[0098]

[0098] The compositions described herein may, in certain embodiments, be administered orally, parenterally, or topically via a single dose or in divided doses. Administration of the compounds may vary from continuous (intravenous infusion) to multiple oral doses per day (e.g., QID) and may include, among other routes of administration, oral, topical, parenteral, intramuscular, intravenous, subcutaneous, transdermal (may include penetration enhancers), buccal, sublingual, and suppository administration, by inhalation spray, rectally, vaginally, or via implanted reservoir. Enteric-coated oral tablets may also be used to improve the bioavailability of the compounds from the oral administration route. The most effective dose form will vary depending on the pharmacokinetics of the particular agent selected and the severity of the disease in the patient. Administration of the compounds according to this disclosure as sprays, mists, or aerosols for intranasal, intratracheal, or pulmonary administration may also be used. Therefore, this disclosure also relates to pharmaceutical compositions comprising an effective amount of the compounds according to this disclosure, optionally combined with pharmaceutically acceptable carriers, excipients, or additives. The compounds according to this disclosure may be administered in immediate-release, intermediate-release, or sustained-release or controlled-release forms. Sustained-release or controlled-release forms are preferably administered orally, but may also be administered by suppositories, and transdermally or in other topical forms. Intramuscular injection in liposome form may also be used to control or maintain the release of the compounds at the injection site.

[0099]

[0099] Accordingly, in one embodiment, pharmaceutical formulations of the compounds described herein can be prepared for parenteral administration by a pharmaceutically acceptable parenteral vehicle and in an injectable form of a unit dose. As used herein, the term “parenteral” includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intrafocal and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally or intravenously.

[0100]

[0100] The compositions of the present disclosure can be formulated conventionally using one or more pharmaceutically acceptable carriers and can also be administered in controlled-release formulations. The compounds of the present disclosure can be formulated as pharmaceutical compositions in accordance with standard pharmaceutical regulations. According to this embodiment, pharmaceutical compositions are provided comprising the compounds described herein in association with one or more pharmaceutically acceptable additives.

[0101]

[0101] Typical formulations are prepared by mixing the compounds of this disclosure with additives, such as carriers and / or diluents. Suitable carriers, diluents and other additives are well known to those skilled in the art and include materials such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, and water. The specific carrier, diluent or other additive used depends on the means and purpose for which the compound is utilized. Other pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffers such as phosphates, glycine, sorbic acid, potassium sorbate, and partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block copolymers, polyethylene glycol, and lanolin fat).

[0102]

[0102] The solvent is generally selected based on solvents that are recognized by those skilled in the art as being safe to administer to mammals (GRAS). Generally, safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble in or miscible with water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycol (e.g., PEG400, PEG300), and mixtures thereof. Permitted diluents, carriers, additives, and stabilizers are non-toxic to the recipient at the dose and concentration used and include buffers and other organic acids such as phosphoric acid, citrate, and methionine; antioxidants including ascorbic acid and methionine; preservatives (octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl, or benzyl alcohol; alkylparabens such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol, etc.); low molecular weight (less than approximately 10 residues) polypeptides; serum Proteins such as lubumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG).

[0103]

[0103] The formulation may also contain one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, flow enhancers, processing aids, colorants, sweeteners, fragrances, flavorings, and other known additives for presentation or to assist in the manufacture of pharmaceuticals. The formulation may be prepared using conventional dissolution and mixing procedures.

[0104]

[0104] The formulation may be prepared by mixing the compound with a physiologically acceptable carrier, i.e., a carrier that is nontoxic to the recipient at the dose and concentration used, at ambient temperature, at an appropriate pH, and to a desired degree of purity. The pH of the formulation may be in the range of about 3 to about 8, although this depends mainly on the specific application and the concentration of the compound. A formulation in an acetate buffer at pH 5 is a suitable embodiment.

[0105]

[0105] The pharmaceutical composition may be in the form of a sterile injectable preparation, such as an aqueous or oily sterile injectable suspension. Preparations used for in vivo administration must be sterile. Such sterilization is readily achieved by filtration through a sterile filtration membrane. The suspension may be formulated according to known techniques using these preferred dispersants or wetting agents and suspending agents described above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable diluent or solvent such as 1,3-butanediol. The sterile injectable preparation may also be prepared as a lyophilized powder. Acceptable additives and solvents that may be used include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile non-volatile oils may conventionally be used as solvents or suspensions. For this purpose, any non-irritating non-volatile oil, including synthetic monoglycerides or synthetic diglycerides, may be employed. Furthermore, fatty acids such as oleic acid can also be used in the preparation of injectable solutions and naturally pharmaceutically acceptable oils, such as olive oil or castor oil, in particular polyoxyethylated versions thereof. Such oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as Ph. Helv or similar alcohols.

[0106]

[0106] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain antioxidants, buffers, bacteriostatic agents, and solutes that are isotonic with the blood of the recipient of the formulation, as well as aqueous and non-aqueous sterile suspensions that may contain suspending agents and thickeners.

[0107]

[0107] The pharmaceutical compositions described herein can be administered orally in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions, or solutions. For tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also usually added. Useful diluents for oral administration in capsule form include lactose and dried corn starch. If an aqueous suspension is required for oral use, the active ingredient is combined with an emulsifier and a suspending agent. Certain sweeteners, flavorings, or colorants may also be added as desired.

[0108]

[0108] Alternatively, the pharmaceutical compositions described herein may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the drug with a suitable non-irritating additive that is solid at room temperature but liquid at rectal temperature, and therefore dissolves in the rectum to release the drug. Examples of such materials include cocoa butter, beeswax, and polyethylene glycol.

[0109]

[0109] The pharmaceutical compositions described herein can also be administered topically. Suitable topical formulations can be rapidly prepared for each of these areas or organs. Topical administration to the lower gastrointestinal tract can be achieved by anal suppositories (see above) or suitable enema formulations. Topically receptive transdermal patches can also be used.

[0110]

[0110] With regard to topical administration, the pharmaceutical composition may be formulated in a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water. In a particular preferred embodiment of this disclosure, the compound may be a stent that is surgically implanted in a patient to inhibit or reduce the possibility of occlusion occurring in the stent within the patient.

[0111]

[0111] Alternatively, the pharmaceutical composition may be formulated as a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[0112]

[0112] For use in ophthalmology, the pharmaceutical composition can be formulated as a finely powdered suspension of isotonic pH-adjusted sterile saline, or preferably as a solution of isotonic pH-adjusted sterile saline, with or without a preservative such as benzylalkonium chloride. Alternatively, for use in ophthalmology, the pharmaceutical composition may be incorporated into an ointment such as petrolatum.

[0113]

[0113] The pharmaceutical compositions of this disclosure may also be administered by nasal aerosol or inhalation. Such compositions may be prepared according to the art known in the art of formulation and may be prepared as a saline solution using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizers or dispersants.

[0114]

[0114] Pharmaceutical compositions comprising the compounds of this disclosure can be formulated, prescribed, and administered in a manner that is fully medically appropriate, i.e., in terms of quantity, concentration, schedule, process, vehicle, and route of administration. Factors to be considered in this regard include the specific disorder being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of drug delivery, the method of administration, the administration plan, and other factors known to medical professionals. The “therapeutically effective amount” of the compound administered is the minimum amount necessary to prevent, improve, or treat the disorder, controlled by such considerations. Such an amount is preferably below the amount that is toxic to the host or makes the host more susceptible to unnecessary side effects.

[0115]

[0115] The compounds described herein can be formulated into pharmaceutical dose formulations to provide easily controllable drug doses and enable patient compliance in a given regimen. Pharmaceutical compositions (or formulations) for application may be packaged in a variety of forms depending on the method used to administer the drug. Generally, dispensing articles include containers in which the pharmaceutical formulation is placed in a suitable form. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, and metal cylinders. Containers may include tamper-evident assemblies to prevent unintentional access to the contents of the package. In addition, containers have labels on them that describe the contents of the container. Labels may also include appropriate cautionary notes.

[0116]

[0116] The formulations may be packaged in unit dose or multi-dose containers, such as sealed ampoules and vials, and may be stored under freeze-drying conditions, requiring only the addition of a sterile liquid carrier, such as water, for injection immediately before use. Immediate-acting injectable solutions and suspensions are prepared from the sterile po...

Claims

1. Compound of formula (I): [Transformation 50] or its stereoisomer or tautomer, or any of the aforementioned pharmaceutically acceptable salts [in the formula, I) L １ -R １ is methyl; L ２ is a bond or -CH ２ - and; R ２ teeth, i) May be substituted with one or more halos -O-C ６ It is an allele; ii) One or more -C(O)O-C １－６ A six-membered heterocycline which may be substituted with alkyl; iii) one or more R ｓ -substituted 6- to 9-membered heteroaryl; wherein R ｓ is independently at each occurrence halo or C １－１２ alkyl; or iv) One or more -C(O)O-C １－６ C may be substituted with alkyl. ６ It is cycloalkyl, or, II) L ２ -R ２ It is cyclopropyl; L １ The bond is -CH ２ -ien-CH ２ CH ２ -ien-CH ２ CH ２ CH ２ -, -C(CH ３ ) ２ -, -CH(CH ２ OH)-, -CH(CH ２ CH ３ )-,-CH(CH ３ )CH ２ -, or -CH(CH ２ CH ３ )CH ２ - and; R １ teeth, i) -L ３ -C ６ It is aryl; here, L ３ is O or C(O)NH; -L ３ -C ６ Aryl's C ６ Aaryl is one or more Halo C １－６ It may also be substituted with alkyl; ii) One or more R ｓ C may be replaced with ６－１１ It is a cycloalkyl, where R ｓ Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. １－６ It is alkyl; iii) One or more R ｓ C may be replaced with ６ It is aryl; here, R ｓ Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R ｓ The 5-20 member heteroaryl has one or more ring atoms independently selected from N and O; R ｓ The 5-20 member heteroaryl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independent of C １－６ It is alkyl; iv) One or more R ｓ It is a 5-9 member heteroaryl which may be substituted with; where R ｓ Each instance of appearance independently involves Halo, Amine, and C. １－６ Alkyl, or C ６－２０ It is an allele; R ｓ C ６－２０ A aryl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independently a halo; or v) One or more R ｓ A 4-10 member heterocyclyl which may be substituted with; where R ｓ Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. ６－２０ Aryl, or C １－６ It is alkyl; R ｓ C １－６ Alkyl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independent of C ６－２０ It is Ariel, R ｓ C ６－２０ A aryl is one or more R ｕ It may be replaced by; here, R ｕ Each appearance is independent of whether it is a halo or C. １－６ It is alkyl.

2. L １ -R １ is methyl; L ２ is a bond or -CH ２ - and; R ２ teeth, i) May be substituted with one or more halos -O-C ６ It is an allele; ii) One or more -C(O)O-C １－６ A six-membered heterocycline which may be substituted with alkyl; iii) One or more R ｓ It is a 6- to 9-member heteroaryl substituted with; where R ｓ Each appearance is independent of whether it is a halo or C. １－１２ Alkyl; or iv) One or more -C(O)O-C １－６ C may be substituted with alkyl. ６ It is a cycloalkyl, The compound described in claim 1, or its stereoisomer or tautomer, or any of the pharmaceutically acceptable salts described above.

3. L ２ -R ２ It is cyclopropyl; L １ is a bond, -CH ２ -, -CH ２ CH ２ -, -CH ２ CH ２ CH ２ -, -C(CH ３ ) ２ -, -CH(CH ２ OH)-, -CH(CH ２ CH ３ )-, -CH(CH ３ )CH ２ -, or -CH(CH ２ CH ３ )CH ２ -; R １ teeth, i) -L ３ -C ６ It is aryl; here, L ３ is O or C(O)NH; -L ３ -C ６ Aryl's C ６ Aaryl is one or more Halo C １－６ It may also be substituted with alkyl; ii) One or more R ｓ C may be replaced with ６－１１ It is a cycloalkyl, where R ｓ Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. １－６ It is alkyl; iii) One or more R ｓ C may be replaced with ６ It is aryl; here, R ｓ Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R ｓ The 5-20 member heteroaryl has one or more ring atoms independently selected from N and O; R ｓ The 5-20 member heteroaryl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independent of C １－６ It is alkyl; iv) One or more R ｓ It is a 5-9 member heteroaryl which may be substituted with; where R ｓ Each instance of appearance independently involves Halo, Amine, and C. １－６ Alkyl, or C ６－２０ It is an allele; R ｓ C ６－２０ A aryl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independently a halo; or v) One or more R ｓ A 4-10 member heterocyclyl which may be substituted with; where R ｓ Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. ６－２０ Aryl, or C １－６ It is alkyl; R ｓ C １－６ Alkyl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independent of C ６－２０ It is Ariel, R ｓ C ６－２０ A aryl is one or more R ｕ It may be replaced by; here, R ｕ Each appearance is independent of whether it is a halo or C. １－６ It is alkyl. The compound described in claim 1, or its stereoisomer or tautomer, or any of the pharmaceutically acceptable salts described above.

4. L １ -R １ is methyl; L ２ is a bond or -CH ２ - and; R ２ -O-C may be substituted with one or more halos. ６ It is Ariel. The compound according to claim 1 or 2, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

5. L １ -R １ is methyl; L ２ is a bond or -CH ２ - and; R ２ is one or more -C(O)O-C １－６ It is a six-membered heterocycline which may be substituted with alkyl groups. The compound according to claim 1 or 2, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

6. L １ -R １ is methyl; L ２ is a bond or -CH ２ - and; R ２ is one or more R ｓ It is a 6- to 9-member heteroaryl substituted with; where R ｓ Each appearance is independent of whether it is a halo or C. １－１２ It is alkyl. The compound according to claim 1 or 2, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

7. L １ -R １ is methyl; L ２ is a bond or -CH ２ - and; R ２ is one or more -C(O)O-C １－６ C may be substituted with alkyl. ６ It is a cycloalkyl, The compound according to claim 1 or 2, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

8. L ２ -R ２ It is cyclopropyl; L １ The bond is -CH ２ -ien-CH ２ CH ２ -ien-CH ２ CH ２ CH ２ -, -C(CH ３ ) ２ -, -CH(CH ２ OH)-, -CH(CH ２ CH ３ )-,-CH(CH ３ )CH ２ -, or -CH(CH ２ CH ３ )CH ２ - and; R １ Ha-L ３ -C ６ It is aryl; here, L ３ is O or C(O)NH; -L ３ -C ６ Aryl's C ６ Aaryl is one or more Halo C １－６ It may be substituted with alkyl. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

9. L ２ -R ２ It is cyclopropyl; L １ The bond is -CH ２ -ien-CH ２ CH ２ -ien-CH ２ CH ２ CH ２ -, -C(CH ３ ) ２ -, -CH(CH ２ OH)-, -CH(CH ２ CH ３ )-,-CH(CH ３ )CH ２ -, or -CH(CH ２ CH ３ )CH ２ And; R １ is one or more R ｓ C may be replaced with ６－１１ It is a cycloalkyl; where R ｓ Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. １－６ It is alkyl. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

10. L ２ -R ２ It is cyclopropyl; L １ The bond is -CH ２ -ien-CH ２ CH ２ -ien-CH ２ CH ２ CH ２ -, -C(CH ３ ) ２ -, -CH(CH ２ OH)-, -CH(CH ２ CH ３ )-,-CH(CH ３ )CH ２ -, or -CH(CH ２ CH ３ )CH ２ And; R １ is one or more R ｓ C may be replaced with ６ It is aryl; here, R ｓ Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R ｓ The 5-20 member heteroaryl has one or more ring atoms independently selected from N and O; R ｓ The 5-20 member heteroaryl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independent of C １－６ It is alkyl. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

11. L ２ -R ２ It is cyclopropyl; L １ The bond is -CH ２ -ien-CH ２ CH ２ -ien-CH ２ CH ２ CH ２ -, -C(CH ３ ) ２ -, -CH(CH ２ OH)-, -CH(CH ２ CH ３ )-,-CH(CH ３ )CH ２ -, or -CH(CH ２ CH ３ )CH ２ And; R １ is one or more R ｓ It is a 5-9 member heteroaryl which may be substituted with; where R ｓ Each instance of appearance independently involves Halo, Amine, and C. １－６ Alkyl, or C ６－２０ It is an allele; R ｓ C ６－２０ A aryl is one or more R ｔ It may be replaced by; here, R ｔ Each instance of appearance is independently a halo. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

12. L ２ -R ２ It is cyclopropyl; L １ The bond is -CH ２ -ien-CH ２ CH ２ -ien-CH ２ CH ２ CH ２ -, -C(CH ３ ) ２ -, -CH(CH ２ OH)-, -CH(CH ２ CH ３ )-,-CH(CH ３ )CH ２ -, or -CH(CH ２ CH ３ )CH ２ And; R １ is one or more R ｓ A 4-10 member heterocyclyl which may be substituted with; where R ｓ Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. ６－２０ Aryl, or C １－６ It is alkyl; R ｓ C １－６ Alkyl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independent of C ６－２０ It is Ariel, R ｓ C ６－２０ A aryl is one or more R ｕ It may be replaced by; here, R ｕ Each appearance is independent of whether it is a halo or C. １－６ It is alkyl. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

13. L １ -R １ is methyl; L ２ is a bond or -CH ２ - and; R ２ teeth, 【Chemistry 51】 Selected from the group consisting of, The compound according to claim 1 or 2, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

14. L １ -R １ is methyl; L ２ is a combination; R ２ teeth, 【Chemistry 52】 Selected from the group consisting of, A compound according to claim 1, 2, or 13, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

15. L １ -R １ is methyl; L ２ is, -CH ２ - and; R ２ teeth, 【Chemistry 53】 Selected from the group consisting of, A compound according to claim 1, 2, or 13, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

16. L ２ -R ２ It is cyclopropyl; L １ The bond is -CH ２ -ien-CH ２ CH ２ -ien-CH ２ CH ２ CH ２ -, -C(CH ３ ) ２ -, -CH(CH ２ OH)-, -CH(CH ２ CH ３ )-,-CH(CH ３ )CH ２ -, or -CH(CH ２ CH ３ )CH ２ And; R １ teeth, 【Chemistry 54】 Selected from the group consisting of, A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or any of the pharmaceutically acceptable salts described above.

17. L ２ -R ２ It is cyclopropyl; L １ is a combination; R １ teeth, 【Transformation 55】 Selected from the group consisting of, A compound according to claim 1, 3, or 16, or a stereoisomer or tautomer thereof, or any of the aforementioned pharmaceutically acceptable salts.

18. L ２ -R ２ It is cyclopropyl; L １ is, -CH ２ -ien-CH ２ CH ２ -ien-CH ２ CH ２ CH ２ -, -C(CH ３ ) ２ -, -CH(CH ２ OH)-, -CH(CH ２ CH ３ )-,-CH(CH ３ )CH ２ -, and -CH(CH ２ CH ３ )CH ２ Selected from the group consisting of: R １ teeth, 【Transformation 56】 Selected from the group consisting of, A compound according to claim 1, 3, or 16, or a stereoisomer or tautomer thereof, or any of the aforementioned pharmaceutically acceptable salts.

19. The aforementioned compound, 【Chemistry 57】 [Chem. 58] A compound according to claim 1, selected from the group consisting of the above, or a stereoisomer or tautomer thereof, or any of the aforementioned pharmaceutically acceptable salts.

20. A compound, or its stereoisomer or tautomer, or any of the aforementioned pharmaceutically acceptable salts, wherein the compound is 【Chemistry 58-1】 【Chemistry 58-2】 【Chemistry 58-3】 A compound, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof, selected from the group consisting of the above.

21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20, or a stereoisomer or tautomer thereof, or any of the aforementioned pharmaceutically acceptable salts, and one or more pharmaceutically acceptable additives.

22. A composition for use in the treatment of diseases or indications related to VHL activity, comprising a compound according to any one of claims 1 to 20, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof.

23. The composition according to claim 22, wherein the disease or indication is a hyperproliferative disorder, anemia, or ischemia.

24. The composition according to claim 23, wherein the hyperproliferative disorder is a solid tumor.

25. The composition according to claim 24, wherein the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma.

26. A composition for use in the treatment of a VHL activity-related disease or indication in a subject requiring treatment for a VHL activity-related disease or indication, comprising a compound according to any one of claims 1 to 20, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof.

27. Compound of formula (II): 【Chemistry 59】 or its stereoisomer or tautomer, or any of the aforementioned pharmaceutically acceptable salts [in the formula, I) L １ -R １ is methyl; L ２ is a bond or -CH ２ - and; R ２ teeth, i) May be substituted with one or more halos -O-C ６ It is an allele; ii) One or more -C(O)O-C １－６ A six-membered heterocycline which may be substituted with alkyl; iii) One or more R ｓ It is a 6- to 9-member heteroaryl substituted with; where R ｓ Each appearance is independent of whether it is a halo or C. １－１２ It is alkyl; iv) One or more -C(O)O-C １－６ C may be substituted with alkyl. ６ It is cycloalkyl; v) - N(CH ３ )-C ６ It is an allele; or vi) One or more R ｓ C may be replaced with ６ It is aryl, and here, R ｓ Each occurrence is independent of C １－６ It is a haloalkyl; or II) L ２ -R ２ It is cyclopropyl; L １ The bond is -CH ２ -ien-CH ２ CH ２ -ien-CH ２ CH ２ CH ２ -, -C(CH ３ ) ２ -, -CH(CH ２ OH)-, -CH(CH ２ CH ３ )-,-CH(CH ３ )CH ２ -, or -CH(CH ２ CH ３ )CH ２ - and; R １ teeth, i) -L ３ -C ６ It is aryl; here, L ３ is O or C(O)NH; -L ３ -C ６ Aryl's C ６ Aaryl is one or more Halo C １－６ It may also be substituted with alkyl; ii) One or more R ｓ C may be replaced with ６－１１ It is a cycloalkyl, where R ｓ Each occurrence independently produces a halo, a 5-20 member heteroaryl, or S(O)C. １－６ It is alkyl; iii) One or more R ｓ C may be replaced with ６ It is aryl; here, R ｓ Each occurrence is independently a halo, cyano, or 5-20 member heteroaryl; R ｓ The 5-20 member heteroaryl has one or more ring atoms independently selected from N and O; R ｓ The 5-20 member heteroaryl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independent of C １－６ It is alkyl; iv) One or more R ｓ It is a 5-9 member heteroaryl which may be substituted with; where R ｓ Each instance of appearance independently involves Halo, Amine, and C. １－６ Alkyl, or C ６－２０ It is an allele; R ｓ C ６－２０ A aryl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independently a halo; or v) One or more R ｓ A 4-10 member heterocyclyl which may be substituted with; where R ｓ Each instance independently produces a halo, oxo, hydroxyl, 5-20 member heteroaryl, and C. ６－２０ Aryl, or C １－６ It is alkyl; R ｓ C １－６ Alkyl is one or more R ｔ It may be replaced by; here, R ｔ Each occurrence is independent of C ６－２０ It is Ariel, R ｓ C ６－２０ A aryl is one or more R ｕ It may be replaced by; here, R ｕ Each appearance is independent of whether it is a halo or C. １－６ It is alkyl.

28. A pharmaceutical composition comprising the compound described in claim 27, or a stereoisomer or tautomer thereof, or any of the aforementioned pharmaceutically acceptable salts, and one or more pharmaceutically acceptable additives.

29. A composition comprising the compound according to claim 27, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof, for use in the treatment of diseases or indications related to VHL activity.

30. The composition according to claim 29, wherein the disease or indication is a hyperproliferative disorder, anemia, or ischemia.

31. The composition according to claim 30, wherein the hyperproliferative disorder is a solid tumor.

32. The composition according to claim 31, wherein the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma.

33. A composition for use in the treatment of a VHL activity-related disease or indication in a subject requiring treatment for a VHL activity-related disease or indication, comprising the compound described in claim 27, or a stereoisomer or tautomer thereof, or any pharmaceutically acceptable salt thereof.

Images